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“Doctors are men who prescribe medicines of which they know little, to cure 
diseases of which they know less, in human beings of whom they know nothing” 
 
François-Marie Arouet-Voltaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
       Ad Alessandro e Anastasia 
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Parkinson’s disease (PD) is the second most common neurodegenerative disease, 
after Alzheimer’s disease, and the most common movement disorder. Drug treatment 
and deep brain stimulation can ameliorate symptoms, but the progressive degeneration 
of dopaminergic neurons in the substantia nigra eventually leads to severe motor 
dysfunction. While some effective treatments for patients with PD exist, these treatment 
strategies are mainly symptomatic and aimed at increasing dopamine levels in the 
degenerating nigrostriatal system.  Existing drugs are limited in their relief and 
decrease in effectiveness as PD progresses.The transplantation of stem cells has 
emerged as a promising approach to replace lost neurons in order to restore dopamine 
levels in the striatum and reactivate functional circuits. Post mortem neural precursor 
cells (PM-NPCs) are  a subclass of sub ventricular zone (SVZ)-derived neural 
progenitors, capable of surviving many hours (16 hours) after donor death. The in vitro 
differentiation yields more neurons (about 30-40%) compared to regular NPCs (Marfia 
et al., 2011). Recently from the SVZ of a transgenic mouse strain expressing green 
fluorescent protein (GFP) under the promoter C of the ubiquitin gene [(C57BL/6-
Tg(UBC-GFP)30Scha/J)] we isolated GFP PM-NPCs, from mice at 6 hours after the 
donor death. These cells were characterized and their potential of in terms of 
replacement therapy was investigated in a mouse model of Parkinson disease. The 
degeneration of dopaminergic neurons was obtained through the administration of  1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at the dosage of 36 mg/kg 
intraperiteoneally (i.p.). After 1 week the lesion was stabilized by a second 
administration (i.p.) of the neurotoxin at the dosage of 20 mg/kg. 1x 105 of PM-PCs-
GFP were injected unilaterally into the striatum of C57/BL mice by using specific 
stereotaxic coordinates 3 days after the second MPTP administration. The effects of 
transplanted cells were determined by means of performance tests aimed at detecting 
behavioral improvements. Moreover, the neurochemical changes were also studied by 
high performance liquid chromatography (HPLC). In order to  study the in vivo fate of 
grafted GFP PM-NPCs animals were perfused 2 weeks after transplantation and 
immunohistochemistry  studies were performed. Our results show that animals grafted 
with GFP PM-NPCs determined a remarkable improvement of behavioral parameters 
measured by means of both horizontal and vertical grid tests (forepaw fault and time 
required to grab on the grids while turning and climbing down) since the third day after 
transplantation.  These improvements were very significant and the average values 
were close to control animals. This was maintained during all the two weeks of 
experimental observation. By means of immunofluorescence staining we observed that 
the majority  of transplanted GFP-PM-NPCs were vital and able to migrate ventrally 
and caudally from the injection site lengths as far as 1000 microns into the striatum, 
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and could reach the ipsilateral and contralateral substantia nigra pars compacta. 
Moreover, morphological analyses revealed that transplanted cells in the striatum are 
able to differentiate into tyrosine hydroxylase (40%), cholinergic (40%), and gabaergic 
neurons (25%). This study provides new evidences that PM-NPCs will be useful for 
developing cellular PD therapies. Future studies should further explore the clinical 
potential role of the investigated post mortem neural precursors cells  in order to 
provide new perspectives for PD treatment.   
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2.1 Regenerative medicine 
Regenerative medicine is an emerging field that combine the knowledge and skill 
of many disciplines with the aim of healing impaired function in the body 
(Haseltine 2003; Gutmann et al. 2005). The regeneration of tissues and organs 
offers a radical new approach for the treatment of injury and disease, but the 
main goal of regenerative medicine is not only the replacement of what is 
malfunctioning in the body, but to provide the biological requirements 
fundamental for in vivo repair, to devise replacements that seamlessly interact 
with the living body, and to stimulate the body's intrinsic capacities for 
regeneration (Greenwood et al, 2006). Regenerative medicine take advantage of 
the combination of several technological approaches that moves it beyond 
traditional transplantation and replacement therapies. These approaches may 
include, but are not limited to, the use of stem cells, soluble molecules, genetic 
engineering, tissue engineering, and advanced cell therapy (Greenwood et al, 
2006). The United States National Academies of Science report, Stem Cells and 
the Future of Regenerative Medicine, estimates that the potential patient 
populations in the US for stem cell–based therapies include more than a hundred 
million patients affected by diseases such as cardiovascular conditions, 
autoimmune diseases, diabetes, cancer, neurodegenerative diseases, and burns 
(Petit-Zeman et al,  2001). The following table shows some of pathologies in 
which the potential application of a regenerative medicine could improve the 
patients’ health.    
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Figure 1. Top Ten Regenerative Medicine Applications for Improving Health in 
Developing Countries (Greenwood et al,  2006). 
The current approaches are influenced by our understanding of embryonic 
development, of tissue turnover and replacement in adult animals (Alonso et al., 
2003, Harada et al, 2003, Radtke et al.,  2005), and by tissue engineering and 
stem cell biology (Stocum, 2004). The regeneration of organs and appendages 
after injury occurs in diverse animal groups and provides another important 
viewpoint, in addition to the demonstration that complex adult tissues can be 
rebuilt. 
Regenerative medicine currently is based on three approaches (Figure 2) 
(Stocum, 2004): the transplantation of stem cells to build new structures, the 
transplantation of cells pre-primed (genetically or chemically) to develop in a 
given tissue, and the “induction” of endogenous cells to replace missing 
structures. Each of the different aspects identified in the first two examples—the 
generation of an appropriate cohort of regenerative cells, their regulated division 
and differentiation, and the restoration of the appropriate part of the structure—
must be stimulated from endogenous cells in the third approach. 
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Figure 2. Schematic of three approaches on which is based regenerative medicine. 
(A) Implantation of stem cells (light green) from culture leads to the restoration of the 
structure. (B) Stem cells are provided with a scaffold (triangle) in order to guide 
restoration. (C) The residual cells of the structure are induced to make a regenerative 
response (from Stocum et al 2004).  
Stem cell therapy has only been established as a clinical standard of care for 
diseases of the blood system. However, there are a growing number of clinics 
throughout the world that are testing stem cell interventions and some that are 
claiming to offer stem cell treatments for a variety of conditions without clear 
evidence of safety or efficacy. For the successful application of novel stem cell-
based approaches, it will be necessary to define the scientific and clinical 
advances, as well as the associated regulatory, ethical, and societal issues, that 
need to be addressed in order to deliver treatments safely, effectively, and fairly 
(Hyun et al., 2008). 
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Figure 3. The scientific challenges of stem cells research in regenerative medicine. 
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2.2 Parkinson’s disease 
Parkinson's disease (PD) is a common neurodegenerative disorder—a 
synucleinopathy—with a prevalence of 160/100 000 in Western Europe rising to 
∼4% of the population over 80 (http://www.epda.eu.com). With an ageing 
population, the management of PD is likely to prove an increasingly important 
and challenging aspect of medical practice for neurologists and general 
physicians. Our understanding of the pathogenesis of the disease has been 
advanced in the last decade with the identification of several gene mutations 
which may shed light on the mechanisms of pathogenesis in sporadic cases of 
PD.  
 
The diagnosis of PD remains essentially a clinical one, and it is important to 
recognize the early features together with symptoms and signs suggesting other 
causes of parkinsonism. There has also been a rapid expansion in the treatment 
options both in the early and in the later stages of the illness together with a 
greater awareness of non-motor complications. 
 
The most unique and obvious sign of parkinson is the hand tremor, often 
described as "pill rolling". Uncontrollable shaking of a hand or arm occurs on one 
or both sides of the body. Tremors can also occur in the legs, feet, or chin. 
Shaking lessens as the affected area is used (it is also called a resting tremor) 
and stops completely during sleep (Poewe et al., 1998).  
 
 
Muscle rigidity: 
Muscles can become tight and rigid as they fail to receive messages from the 
brain to relax. Thus the resulting muscle spasm further slows movement. This 
can cause muscle aches, a stooped posture, and slow movement. Walking may 
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be limited to short, shuffling steps. Climbing stairs or getting out of a chair or a 
bed may take extra effort.  
Often people with Parkinson's disease become "frozen" - unable to continue 
movement at all. In this case, help may be needed to resume movement by 
"putting a foot in front of the patient to step over" or suggesting that they are 
"stepping over lines" (Bhat and Weiner 2005).  
 
 
Postural instability:  
Parkinson's disease can give problems with balance, causing the individual to fall 
overset of movements. Muscles simply do not work as rapidly as they should. It's 
as if the messages from the brain take a detour, sometimes even getting lost 
before arriving at their destination. Rapid, coordinated movements like writing, 
speaking, typing or dancing are most affected.  
 
 
 
Maintaining posture requires rapid adjustments in response to changing forces 
on the body, adjustments that are not possible due to the slowed movement and 
stiffened muscles of parkinsonism (Scott L. 2006).  
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Bradykinesia:  
The word bradykinesia means simply slowed movements (Scott L. 2006) 
 
Other symptoms:  
Other symptoms may include speaking softly in a monotone voice, and difficulty 
with swallowing and writing.  
Constipation is also a common problem.  
Depression, feelings of insecurity and fear often bring distress to the patient and 
can make it difficult to cope with the illness, both for the patient and for relatives 
(Scott L. 2006). 
 
Combination of symptoms: picture of the patient 
These disabilities combine to produce a number of specific characteristics in a 
patient with Parkinson's which; taken together, make up the disease also known 
as paralysis agitans.  
The full picture of the disease includes (Scott L., 2006):  
 The typical hand tremor 
 A stooped posture 
 A short, shuffling gait with no associated arm movements 
 A tendency to fall over, either forwards or backwards 
 Difficulty both in starting to walk and in stopping 
 Difficulty rolling over in bed and in getting in and out of a car or chair 
 Poorly coordinated hand use 
 Small handwriting  
 A face that is empty of expression -- the so-called "Parkinson's Mask"  
 Soft speech  
 Drooling and difficulty swallowing, caused by uncoordinated movements of the 
throat and mouth. 
2.3 Pathology, aetiology and pathogenesis of Parkinson’s Disease 
The pathological hallmark of PD is cell loss within the substantia nigra particularly 
affecting the ventral component of the pars compacta. By the time of death, this 
region of the brain has lost 50–70% of its neurons compared with the same 
region in unaffected individuals.  
 
The earliest documented pathological changes in PD have been observed in the 
medulla oblongata/pontine tegmentum and olfactory bulb. In these early stages—
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Braak stages 1 and 2—patients are pre-symptomatic. As the disease advances—
Braak stages 3 and 4—the substantia nigra, areas of the midbrain and basal 
forebrain become involved. Finally, the pathological changes appear in the 
neocortex (Davie CA, 2008).  
 
 
Figure 4. This figure shows neuronal pathways that degenerate in Parkinson's Disease. 
Signals that control body movements travel along neurons that project from the 
substantia nigra to the caudate nucleus and putamen (collectively called the striatum). 
These "nigro-striatal" neurons release dopamine at their targets in the striatum. In 
Parkinson's patients, dopamine neurons in the nigro-striatal pathway degenerate for 
unknown reasons. 
 
This pathological staging is based on the distribution of lewy bodies. Lewy bodies 
are the pathological hallmark of PD. They are α-synuclein-immunoreactive 
inclusions made up of a number of neurofilament proteins together with proteins 
responsible for proteolysis. These include ubiquitin, a heat shock protein which 
plays an important role in targeting other proteins for breakdown.  
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Figure 5. Lewy bodies. Brown spots are immunostaining using an antibody specifically 
recognizing an abnormal form of alpha-synuclein (http://www.uphs.upenn.edu) 
 
Mutations in the α-synuclein gene are responsible for some familial forms of PD 
in which lewy bodies are also seen. Mutations in the parkin protein produce a 
parkinsonian syndrome without lewy bodies in juvenile cases suggesting that the 
parkin protein plays an important role in the development of the lewy body. It has 
been shown that parkin facilitates the binding of ubiquitin (ubiquination) to other 
proteins such as the α-synuclein interacting protein synphilin-1 leading to the 
formation of lewy bodies. Lewy bodies are found in PD and Dementia with lewy 
bodies (DLB), but are not a pathological hallmark of any other neurodegenerative 
disease.  
 
The identification of single gene defects in PD has focused interest on the 
ubiquitin-proteasome system (UPS) as one potential candidate in the 
development of cell death. The UPS is important for intracellular proteolysis and 
a large number of intracellular processes that maintain the viability of cells. It 
does this by removing unwanted proteins that are no longer required by the cell. 
Failure of the UPS leads to the abnormal aggregation of proteins including α-
synuclein which are a major component of lewy bodies. One of the first sites for 
LB deposition in early PD is the olfactory bulb. It is, therefore, of interest that a 
disturbance in smell and taste is often one of the earliest clinical features in PD 
raising the possibility that LB formation may be integral for the activation of 
pathways leading to neuronal dysfunction and death.  
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Figure 6. Schematic showing the role of a-synuclein misfolding in aetiology of PD. 
Misfolded alpha-synuclein proteins are converted into pathological oligomers and higher 
order aggregates that form fibrils and deposit into Lewy bodies and Lewy neurites in 
affected neurons of the PD brain. Several consequences of these fibrillar deposits of 
alpha-synuclein have been proposed and are indicated (Lee et al., 2006). 
 
The link between UPS and neurodegeneration has been strengthened by the 
discovery of mutations in genes which code for several ubiquitin-proteasome 
pathway proteins in PD. 
 
2.4 Genetic aspects of Parkinson’s disease 
 
Although PD is usually a sporadic disease, there are a growing number of single 
gene mutations which have been identified. At the time of writing, 11 genes have 
been mapped by genetic linkage with six genes identified: α-synuclein (SNCA), 
ubiquitin C-terminal hydrolase like 1 (UCH-L1), parkin (PRKN), LRRK 2, PINK 1 
and DJ-1 genes. These single gene defects with the notable exception of LRRK 2 
are responsible for only a small number of patients with PD, though more 
importantly their identification and the proteins that they encode for are providing 
significant insight into the disease mechanisms that may be responsible for PD 
and other neurodegenerative diseases. A point mutation of the SNCA gene leads 
to the early onset of PD in affected members in an autosomal dominant pattern. 
Of interest, duplication or triplication of the SNCA gene in affected members 
leads to PD symptoms developing at a later age in the fourth or fifth decades 
raising the possibility that overexpression of SNCA may be a factor in sporadic 
disease.  
 
The LRRK 2 gene (PARK8) is the most common cause of familial or the so-called 
‘sporadic’ PD to date.8 The frequency of LRRK2 mutations in patients with a 
family history of PD is 5–7%. The heterozygous mutation, 2877510 g → A, 
produces a glycine to serine amino acid substitution at codon 2019 (Gly2019 
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ser). This LRRK2 G2019S mutation is the most commonly described, accounting 
for the majority of familial cases and up to 1.6% of cases of idiopathic PD, though 
the prevalence seems to be very variable. The LRRK2 gene encodes for a 
protein named dardarin (derived from the basque word for tremor; the original 
families described came from Spain and England). Lewy bodies have been 
identified in some LRRK 2 cases. Many of the LRRK2 patients reported have 
typical features of PD with onset in middle or late onset. Symptoms at onset may 
be typical of idiopathic PD characterized by unilateral bradykinesia and rigidity, 
with tremor present in some but not all patients.  
 
A number of single gene mutations, e.g. parkin and DJ-1 with an autosomal 
recessive pattern of inheritance, may have a clinical pattern of earlier age of 
onset, a more benign course with good response to levodopa and the presence 
of dystonia. However, it is not possible to identify parkin positive young onset PD 
patients from parkin negative patients on clinical features alone.  
 
There has been a great deal of research into mitochondrial genetics and function 
in PD. Abnormalities in Complex 1 of the oxidative phosphorylation enzyme 
pathway is the most consistent finding, having been detected in PD brains, blood 
platelets and skeletal muscle, although defects in other complexes have also 
been reported. 
 
It appears that the cells of the pars compacta are particularly susceptible to 
oxidative damage. Mitochondrial DNA studies have as yet failed to identify a 
convincing gene mutation to explain the oxidative phosphorylation defects in PD. 
However, it seems likely that a mitochondrial defect may play a role in the 
pathways leading to cell dysfunction and death. The PINK1 gene codes for a 
mitochondrial complex and has been shown to be responsible for an autosomal 
recessive form of PD, though is not a major risk factor for sporadic disease.  
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Figure 7. The cellular pathways causing cell death in PD. Summary of PD-associated 
genes that can cause pathway dysfunction, and ultimately cell death. Mutations to the 
genes LRRK2, GBA1, SNCA, PINK1 and PARK2 affect different cellular processes, but 
all cause PD (from Badger  et al. 2014). 
 
 
2.5 Environmental factors and Parkinson’s disease 
 
Besides age and family history, a number of potential contributing factors, such 
as comorbidities (e.g., diabetes, hypertension) and lifestyle habits (e.g., dietary 
pattern, smoking), have been identified (Barichella  et al 2009; Cereda et al 2011; 
Qiu et al   2011, Riz et al 2007; Sofi et al. 2010; Hernan et al 2002). Also, the role 
of living and working environments has been considered to be of great 
significance. The first demonstration that the active metabolite of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine can cause a sub-acute form of parkinsonism 
(Langston et al 1983) aroused considerable interest in the role of some organic 
pollutants, such as pesticides. Identifying environmental factors that predispose 
to the development of PD has proved elusive. Living in a rural environment 
appears to confer an increased risk of PD, and perhaps causally linked to this 
some but not all epidemiological studies have shown a correlation between 
exposure to pesticide use and wood preservatives. The only consistent 
environmental factor is a strong negative correlation between cigarette smoking 
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and the development of the disease. It is also possible that mitochondrial 
dysfunction in PD is triggered by one or more environmental toxins.  A recent 
published meta-analysis shows that epidemiologic data generally support an 
association between pesticides and the risk of PD (Pezzoli and Cereda, 2013). It 
is well known that some pesticides are toxic to humans after acute exposure to a 
very high amount (poisoning). However, the effects of chronic, low-dose 
exposure to this diverse group of chemicals are not so clear. An analysis of over 
100 epidemiologic studies establishes that pesticide exposure (in the absence of 
poisoning) is indeed linked to PD (Pezzoli and Cereda 2013). Perhaps one of the 
most important unanswered questions is which pesticides are associated with 
PD. Of several specific pesticides or chemical classes of pesticides evaluated in 
the meta-analysis, only the herbicide paraquat was significantly associated with 
PD. But what is needed is detailed information on the nature of exposure—which 
pesticides, at what dose, and for how long—to help design policies and practices 
that prevent the relevant exposures. Genetic susceptibility is one of the factors 
that may modify effects of pesticides on the risk of PD. Studies of gene variants 
related to pesticide metabolism and transport, to mitochondrial dysfunction and 
oxidative stress, and to familial forms of PD suggest that associations of 
pesticides with PD are stronger in genetically susceptible individuals (Cannon 
and Greenamyre 2013). Again, most studies have assessed effects of pesticides 
as a group; studies of genetic susceptibility will prove most fruitful when they 
focus on specific pesticides. Also needed are informations on the cellular and 
molecular mechanisms that, over time, lead from pesticide exposure to 
neurodegeneration and ultimately to PD. 
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Figure 8. Simplified model for mechanisms by which pesticides induce and 
develop chronic disease. 
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2.6 Synthesis, Metabolism and Dopamine transmission 
 
 
Figure 9. Structure of dopamine, the principal neurotransmitter involved in Parkinson’s 
Disease. 
 
The amino acids phenylalanine and tyrosine are the precursors of Dopamine 
(Figure 9). For the most part, mammals convert dietary phenylalanine to tyrosine 
by phenylalanine hydroxylase (predominantly located in the liver). Tyrosine 
crosses readily into the brain through uptake; however, unlike tryptophan, normal 
brain levels of tyrosine are typically saturating. Conversion of tyrosine to L-DOPA 
(3,4-dihydroxyphenylalanine) by the enzyme tyrosine hydroxylase is the rate-
limiting step in the synthesis of DA. Tyrosine hydroxylase is a mixed-function 
enzyme that requires iron and a biopterin co-factor; enzyme activity is regulated 
by phosphorylation and by end-product inhibition. Four alternatively spliced 
isoforms of tyrosine hydroxylase have been identified in humans, which is in 
contrast to many non-human primates (two isoforms) and rat (one isoform). At 
present, it is unclear if these various isoforms play different roles. Once 
generated, L-DOPA is rapidly converted to DA by L-aminoacid aromatic 
decarboxylase (AADC), the same enzyme that generates 5-HT from L-5-
hydroxytryptophan. In the CNS and periphery, AADC activity is very high, and 
basal levels of L-DOPA cannot be readily measured.  
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Figure 10. Schematic of Dopamine Synthesis and Metabolism (from Goodman & 
Gilmans,  Edition 12). 
 
Metabolism of DA occurs primarily by the cellular MAO enzymes localized on 
both pre- and postsynaptic elements. MAO acts on DA to generate an inactive 
aldehyde derivative by oxidative deamination (Figures 5), which is subsequently 
metabolized by aldehyde dehydrogenase to form 3,4-dihydroxyphenylacetic acid 
(DOPAC). 
DOPAC can be further metabolized by catechol-O-methyltransferase (COMT) to 
form homovanillic acid (HVA). Both DOPAC and HVA, as well as DA, are 
excreted in the urine. Levels of DOPAC and HVA are reliable indicators of DA 
turnover; ratios of these metabolites to DA in cerebral spinal fluid serve as 
accurate representations of brain dopaminergic activity. In addition to 
metabolizing DOPAC, COMT also utilizes DA as a substrate to generate 3-
methoxytyramine, which is subsequently converted to HVA by MAO (Goodman & 
Gilman’s Ed. 12).  
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Dopamine neurotransmission 
The neurochemical events that underlie DA neurotransmission are summarized  
in Figure 6. In dopaminergic neurons, synthesized DA is packaged into secretory 
vesicles (or into granules within adrenal chromaffin cells) by the vesicular 
monoamine transporter, VMAT2. This packaging allows DA to be stored in readily 
releasable aliquots and protects the transmitter from further anabolism or 
catabolism. Synaptically released DA is subject to both transporter clearance and 
metabolism. The DA transporter (DAT) is not selective for DA; moreover, DA can 
also be cleared from the synapse by the NE transporter, NET. Reuptake of DA by 
the DA transporter is the primary mechanism for termination of DA action, and 
allows for either vesicular repackaging of transmitter or metabolism. The DA 
transporter is regulated by phosphorylation, offering the potential for DA to 
regulate its own uptake. 
 
 
 
Figure 11. Dopaminergic nerve terminal. Dopamine (DA) is synthesized from tyrosine 
in the nerve terminal by the sequential actions of tyrosine hydrolase (TH) and aromatic 
amino acid decarboxylase (AADC). DA is sequestered by VMAT2 in storage granules 
and released by exocytosis. Synaptic DA activates presynaptic autoreceptors and 
postsynaptic D1 and D2 receptors. Synaptic DA may be taken up into the neuron via the 
DA and NE transporters (DAT, NET), or removed by postsynaptic uptake via OCT3 
transporters. Cytosolic DA is subject to degradation by monoamine oxidase (MAO) and 
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aldehyde dehydrogenase (ALDH) in the neuron, and by catechol-O-methyl transferase 
(COMT) and MAO/ALDH in non-neuronal cells; the final metabolic product is homovanillic 
acid (HVA). 
 
2.7 Clinical diagnosis of PD 
The characteristic features of PD are bradykinesia, rigidity and rest tremor. These 
may not all be present. Postural instability may be a feature, though early 
postural instability backwards particularly with a history of falls is more suggestive 
of progressive supranuclear palsy (PSP). The clinical findings are usually 
asymmetrical in PD. The clinical diagnosis may often appear straightforward, 
though it is worth noting that post-mortem studies have shown an alternative 
diagnosis in up to a quarter of patients with PD diagnosed by general 
neurologists. Of note, there is substantially less diagnostic error in patients 
diagnosed in expert movement disorder clinics which strengthens the argument 
for early referral of patients to specialists expert in movement disorders.  
 
There are a number of other clinical signs that are worth highlighting. A change of 
handwriting with micrographia is often an early feature as is reduced facial 
expression. A loss of arm swing on one side is also an early and useful 
diagnostic feature. A glabellar tap does not seem to be particularly sensitive or 
specific.  
 
A reduced sense of smell is, however, worth asking about since this may be one 
of the first symptoms in early PD.  As the disease becomes more advanced, 
hypophonia, drooling of saliva (from reduced swallowing) and impairment of 
postural reflexes may develop. Non-motor complications of the disease often 
become more troublesome as the disease progresses. It is helpful to enquire 
about symptoms of depression which occurs in ∼40% of PD patients.  
 
The diagnosis of essential tremor should be considered when a patient presents 
with a symmetrical limb tremor, worse with posture and is suppressed by alcohol. 
Head or voice tremor may also be present. In this condition, there may be an 
autosomal dominant inheritance, suppression of the tremor with alcohol and 
there should be no evidence of rigidity or bradykinesia on examination. Adult 
onset dystonia may also present with asymmetrical rest tremor and may explain 
some patients previously labelled as ‘benign tremulous PD’ who have scans with 
no evidence of dopaminergic deficit. Although the diagnosis of PD is a clinical 
one, there are certain situations where investigations can prove useful. 
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Conventional brain imaging with MRI or CT is usually not required unless an 
alternative diagnosis is suspected such as normal pressure hydrocephalus or 
vascular parkinsonism.  
Single photon emission computerized tomography (SPECT) imaging using a 
dopamine transporter (DAT) can be helpful in differentiating PD from a number of 
conditions, including essential tremor and dystonic tremor, neuroleptic-induced 
parkinsonism and psychogenic parkinsonism all of which demonstrate normal 
DAT scans. Uptake within the basal ganglia is reduced in PD, the parkinsonian 
syndromes and DLB. 
 
 
2.8 Existing pharmacological therapies for Parkinson’s Disease 
 
While these are some effective treatments for patients with PD but treatment 
strategies are mainly symptomatic and aimed at increasing dopamine levels in 
the degenerating nigrostriatal system.  
Existing drugs are limited in their relief and decrease in effectiveness as PD 
progresses. Nevertheless, these treatments do not halt the progressive nature of 
PD and are ineffective against gait freezing and postural instability, which are 
more disabling than tremors and rigidity. Further, as PD progresses, drug-
induced motor complications, such as “wearing off” and dyskinesia appear and 
notes that PD dementia is not responsive to dopaminergic therapy and is 
considered the most important factor influencing the daily activities and survival 
of Parkinson’s patients. 
The main families of drugs useful for treating motor symptoms are levodopa 
(usually combined with a dopa decarboxylase inhibitor or COMT inhibitor), 
dopamine agonists and MAO-B inhibitors. The most logical approach to 
correcting this problem is to replace the dopamine (DA). It cannot be taken orally 
as it does not cross the blood brain barrier (BBB). L-dopa therapy is the gold 
standard treatment for Parkinson’s disease. L-dopa is a naturally occurring 
substance. It is in the chemical family of compounds known as amino acids. 
Amino acids are the building blocks of proteins. Its absorption can be reduced if 
taken with a high protein meal. Once absorbed, L-dopa is converted to DA in the 
blood, liver and kidneys. A compound called carbidopa is given with L-dopa. 
Carbidopa inhibits the enzyme in the liver, kidneys, and blood that converts L-
dopa to DA. This allows more L-dopa to pass into the brain. Carbidopa and 
benserazide are peripheral dopa decarboxylase inhibitors, which help to prevent 
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the metabolism of L-DOPA before it reaches the dopaminergic neurons, therefore 
reducing side effects and increasing bioavailability. Levodopa has been related to 
dopamine dysregulation syndrome, which is a compulsive overuse of the 
medication, and punding. Tolcapone inhibits the COMT enzyme, which degrades 
dopamine, thereby prolonging the effects of levodopa. It has been used to 
complement levodopa; however, its usefulness is limited due to its side effects 
such as liver damage. Dopamine agonists were first introduced in the 1970s. 
Dopamine agonists have the capacity to directly stimulate brain dopamine 
receptors. The first generation of dopamine agonists were all ergot derivatives, 
including bromocryptine, cabergoline, dihydroergocriptine, lisuride, and 
pergolide., Also the non-ergot agonist is apomorphine which is a potent mixed 
D1-type and D2- type dopamine agonist receptor agonist with L-dopa-like 
antiparkinsonian effects. Most of the currently used nonergot dopamine agonists 
include pramipexole, ropinirole, rotigotine, and piribedil. Rotigotine is available as 
a once-daily transdermal patch formulation while apomorphine is used as 
subcutaneous infusion treatment for patients with refractory response oscillations 
or as rescue medication for sudden unpredictable off periods. Selegiline and 
rasagiline are both irreversible inhibitors of MAO-B producing dopaminergic 
effects. They inhibit monoamine oxidase-B (MAO-B) which breaks down 
dopamine secreted by the dopaminergic neurons. The reduction in MAO-B 
activity results in increased L-DOPA in the striatum. Selegiline is metabolized to 
methamphetamine and to a lesser extent, to amphetamine which blocks 
dopamine reuptake and releases dopamine and may account for some of the 
dopaminergic effects. Rasagiline even highly potent and does not give rise to 
amphetamine like metabolites, but degrades to aminoindan and selegeline, 
rasagiline and aminoindan have neuroprotective properties. Other drugs such as 
amantadine and anticholinergics may be useful as treatment of motor symptoms. 
Amantadine’s exact mechanism of action remains uncertain, its NMDA receptor–
blocking activity is generally believed to play a major role in producing its anti 
parkinsonian effects. In the 1860s Ordenstein and Charcot were the first to treat 
(PD) by using extracts from Hyscyamus niger, Atropa belladonna, and Datura 
stramonium. With the development of synthetic anticholinergic drugs, they were 
the gold standard for treating PD in the 1940s. 
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2.9 Animal models of Parkinson’s disease: classical toxin-induced rodent 
models 
Over the last two decades, significant strides has been made toward acquiring a 
better knowledge of both the etiology and pathogenesis of Parkinson’s disease 
(PD). Experimental models are of paramount importance to obtain greater 
insights into the pathogenesis of the disease.  
 
 
 
Table 1. Characteristics of Animal Models for Parkinson’s disease 
 
Thus far, neurotoxin based animal models have been the most popular tools 
employed to produce selective neuronal death in both in vitro and in vivo 
systems. These models have been commonly referred to as the pathogenic 
models. 
The two most widely used rodent models of PD are the classical 6-OHDA-treated 
rat and the MPTP-treated mouse.  
 
 
 
Figure 12. Chemical structure of 6-hydroxidopamine (6-OHDA) and MPTP. 
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Of these, the 6-OHDA model has been extensively used as a test bed for novel 
symptomatic agents as well as providing a means for assessing neuroprotective 
and neurorepair strategies. Although unlikely to be the first model of choice for 
testing symptomatic agents, since its behavioural phenotype is less robust than 
the 6-OHDA rat, the MPTP-treated mouse provides a useful secondary screening 
model and has the added advantage of being relatively easy to construct 
compared with the 6-OHDA rat. The characterization of the hydroxylated 
analogue of dopamine, 6-OHDA, as a toxin-inducing degeneration of 
dopaminergic neurons in the nigro-striatal tract (Ungerstedt, 1968) has led to it 
being a widely used tool to induce Parkinsonism in rodents. Unlike MPTP, 6-
OHDA does not efficiently cross the blood–brain barrier and so requires direct 
injection into the brain. 6-OHDA is injected into the nigro-striatal tract at one of 
three locations: into the substantia nigra pars compacta (SNpc) where the A9 
dopaminergic cell bodies are located; into the median forebrain bundle (mfb), 
through which the dopaminergic nigro-striatal tract ascends; or into the terminal 
region, the striatum. Following its injection, 6-OHDA is taken up into the 
dopaminergic neurons via the dopamine transporter, DAT (Figure  13). Given that 
6-OHDA also shows high affinity for the noradrenaline transporter, NET (Luthman 
et al., 1989). Although the exact mechanism behind 6-OHDA toxicity is still 
subject to investigation, current understanding is that, once inside dopaminergic 
neurons, 6-OHDA initiates degeneration through a combination of oxidative 
stress and mitochondrial respiratory dysfunction. Certainly, 6-OHDA readily 
oxidizes to form reactive oxygen species (ROS) such as H2O2 (Mazzio et al., 
2004), to reduce striatal levels of antioxidant enzymes [total glutathione (GSH) or 
superoxide dismutase] (Perumal et al., 1992; Kunikowska and Jenner, 2001), to 
elevate levels of iron in the SN (Oestreicher et al., 1994) and to interact directly 
with complexes I and IV of the mitochondrial respiratory chain, leading to 
subsequent respiratory inhibition and further oxidative stress (Glinka et al., 1997). 
Many of these effects are thought to mirror events occurring in PD brain (Jenner, 
1989), thereby supporting a high degree of construct validity for the 6-OHDA 
model. The 6-OHDA model also mimics many of the biochemical features of PD, 
including reduced levels of striatal dopamine and tyrosine hydroxylase (TH; rate-
limiting step of DA biosynthesis). The 6-OHDA model shares a common failing 
with many other animal models of PD as it does not lead to the formation of the 
pathological hallmark of PD, the Lewy body. Lewy bodies are eosinophilic 
inclusions that contain ubiquitinated proteins such as a-synuclein (Spillantini et 
al., 1997 and 1998) and are associated with lipofuscin-containing lysosomes that 
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have also been shown to accumulate -synuclein in PD brain stem (Braak et al., 
2001). The exact role of Lewy bodies remains to be established, but drugs to 
reduce aggregate formation are considered a potential future strategy for treating 
PD. A recent report of parkin-containing aggregate formation in 6-OHDA-lesioned 
rat (Um et al., 2010) is therefore an exciting advance but requires confirmation. 
The one pathological feature of PD robustly displayed by the 6-OHDA model is 
degeneration of the nigro-striatal tract. The extent of degeneration can be 
established post-mortem by assessing the reduction in various parameters in the 
lesion (ipsilateral) hemisphere, compared with the intact (contralateral) 
hemisphere including number of nissl-stained cells or TH-positive neurons in the 
SNpc; levels of TH or DAT immunoreactivity in the striatum and levels of 
[3H]mazindol binding to DAT in the striatum. Behavioural indices can also be 
taken as a potential pre-screen for predicted lesion size.  
 
MPTP is a commonly used toxin for inducing both rodent and primate models of 
PD based on its ability to induce persistent Parkinsonism in man (Davis et al., 
1979; Langston et al., 1983). Subsequent investigations in non-human primates 
identified that selective destruction of dopaminergic neurons of the nigro-striatal 
tract was the pathological basis 
behind the motor deficits observed (Burns et al., 1983; Jenner et al., 1984; 
Langston et al., 1983), and out of this came the most relevant animal model of 
PD that persists today. The 
impact of the MPTP-treated primate model in the PD field is second to none, but 
first we will focus attention on the use of MPTP in non-primate species. Many 
species, including rats, are insensitive to the toxic effects of MPTP, possibly due 
to the relatively rapid clearance of MPP+, the toxic metabolite of MPTP (Figure 
13; Johannessen et al., 1985). However, specific strains of mice, notably black 
C57, and Swiss Webster are sensitive to MPTP (Sonsalla and Heikkila, 1988) 
and have enabled development of the MPTP mouse model of PD. The 
mechanism behind the neurotoxic action of MPTP has been the subject of 
intense investigation and is relatively well understood (see also Materials and 
Methods paragraph). MPTP is a lipophilic pro-toxin that, following systemic 
injection (usually i.p. or s.c.), rapidly crosses the blood–brain barrier (Riachi et al., 
1989). Once inside the brain, MPTP is converted by MAO-B (principally in glia 
and serotonergic neurons) into the intermediary, 1-methyl-4-phenyl-
2,3,dihydropyridinium (MPDP+) before its rapid and spontaneous oxidation to the 
toxic moiety, 1-methyl-4-phenylpyridinium (MPP+) (Chiba et al., 1984). Following 
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its release into the extracellular space, MPP+ is taken up via DAT into 
dopaminergic neurons where cytoplasmic MPP+ can trigger the production of 
ROS, which may contribute to its overall neurotoxicity (Javitch et al., 1985). 
However, the majority of MPP+ is eventually accumulated within mitochondria 
where the key toxic mechanism occurs. Once inside mitochondria, MPP+ impairs 
mitochondrial respiration via inhibition of complex I of the electron transport 
chain. This action impairs the flow of electrons along the respiratory chain, 
leading to reduced ATP production and the generation of ROS, such as 
superoxide radicals. The combined effects of lowered cellular ATP and elevated 
ROS production are most likely responsible for initiation of cell death-related 
signalling pathways such as p38 mitogen-activated kinase (Karunakaran et al., 
2008), c-jun N-terminal kinase (JNK) (Saporito et al., 2000) and bax (Hassouna 
et al., 1996; Vila et al., 2001), all of which have been demonstrated in vivo 
following MPTP treatment and may contribute to apoptotic cell death (Jackson-
Lewis and Przedborski S, 2007).  The MPTP-treated mouse has some clear 
advantages over the 6-OHDA lesion model, not least of all economic benefits in 
terms of the cheaper costs associated with purchasing and housing mice. Being 
systemically active, MPTP administration does not require the type of skilled 
stereotaxic surgery that production of a 6-OHDA lesion requires. The systemic 
injection also produces a bilateral degeneration of the nigrostriatal tract, more 
reflective of that seen in PD. The MPTP model also mimics many of the known 
biochemical features of PD. For example, in addition to the well-known 
reductions in striatal dopamine and TH, there are also elevated levels of both 
striatal PPE-A (Gudehithlu et al., 1991) and ACh (Hadjiconstantinou et al., 1985). 
Further downstream in the basal ganglia, extracellular glutamate levels have 
been shown to be elevated in the SN of MPTP-treated mice, a rise associated 
with the induction of programmed cell death (Meredith et al., 2009), also 
glutathione (GSH) levels are significantly reduced (Ferraro et al., 1986) as in PD 
itself. Finally, in further support of the face validity of this model, inflammatory 
markers are elevated in the striatum and SN of MPTP-treated mice (Kurkowska-
Jastrzebska et al., 1999; Hebert et al., 2003), which occurs as a result of reactive 
microgliosis in PD. The MPTP model does, however, have some clear 
disadvantages over the 6-OHDA model, particularly in terms of reproducibility 
and the range of behavioural readouts that can be obtained. Mice are far less 
sensitive to MPTP than primates, and the higher doses required can be acutely 
lethal as a result of the peripheral neuro- or cardiotoxicity induced (see Jackson-
Lewis and Przedborski, 2007). Given that the risk of mortality usually occurs 
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within 24 h of the first dose of MPTP and is dose-dependent, the high rates (up to 
50%) seen following acute bolus dosing in the earlier studies (see, e.g., Ferger et 
al., 2000) can be reduced to acceptable levels (<20%) with reductions in the dose 
administered and can be almost completely avoided using alternative protocols in 
which the same or even higher total dose is given in multiple doses (e.g. Gibrat et 
al., 2009). The various dosing regimens used to generate the MPTP mouse 
model have been extensively reviewed  in  Jackson-Lewis and Przedborski, 
2007. In many cases, MPTP is given with probenecid (250 mg·kg-1), a uricosuric 
agent that reduces the renal clearance of MPTP, thereby prolonging its action. 
The most common protocols and the degree of nigrostriatal tract denervation 
produced by these can be summarized as follows: acute bolus, 1 x  30–40 
mg·kg-1 giving 80–90% striatal DA depletion; acute multiple, 2 x 40 mg·kg-1 or 4 
X 12.5–25 mg·kg-1 given at 2 h intervals producing variable 60–90% striatal DA 
loss; sub-acute, 25–40 mg·kg-1/day for 5 days plus  probenecid giving 76% loss 
striatal DA and 60% SNpc cell loss; chronic intermittent, 25 mg·kg-1 twice weekly 
for 5 weeks+ probenecid, giving 95% loss around 1 week, but reducing to a 
stable 70–80% loss by 12 weeks post treatment (Pothakos et al., 2009). Chronic 
infusion can be performed by administration of 20–40 mg·kg-1/day for up to 28 
days given via osmotic minipumps, giving most variable degree of cell loss so far 
ranging from 25% to 80% loss of cells in the SNpc and 28–90% loss of striatal 
dopamine (Fornai et al., 2005; Alvarez-Fischer et al., 2008). The pattern of cell 
death produced is similar to that seen in humans, with the SNpc affected more 
than the VTA , and chronic infusion may also induce loss of noradrenergic cells in 
the locus coeruleus, further resembling the clinical picture (Fornai et al., 2005). 
However, in all cases, the cell death is rapid in onset, with first signs appearing 
within 12–72 h, and is maintained for up to 28 d (Novikova et al., 2006), although 
striatal dopamine depletion may show signs of recovery when using acute or sub-
acute MPTP dosing paradigms (Lau and Meredith, 2003). As noted for the 6-
OHDA model, this rapidity of cell death is not reflective of the disease itself and is 
an obvious weakness of this model. 
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Figure 13. The mechanisms by which neurotoxins kill dopamine neurons involve 
mitochondrial dysfunction and oxidative damage. 6-hydroxydopamine (6-OHDA) is 
taken up by the dopamine transporter and it then generates free radicals. 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) is converted by monoamine oxidase B (MAOB) 
to 1-methyl-4-phenylpyridinium (MPP+). MPP+ is taken up by the dopamine transporter 
and can then be accumulated by mitochondria, leading to complex I inhibition and the 
generation of free radicals, or by the vesicular monoamine transporter, thus reducing 
toxicity. Rotenone is a direct inhibitor of complex I, which also leads to free-radical 
generation. MPTP and rotenone treatment increase the expression of alpha-synuclein 
and, in the latter case, this leads to the formation of Lewy bodies. 
 
2.10 Cell therapy for Parkinson’s Disease 
Cell replacement therapy for treatment of PD is based on the idea that immature 
dopaminergic neurons, following transplantation and functional integration, can 
restore dopaminergic neurotransmission and exert long-lasting effects on motor 
symptoms. Based on data from animal experimentation, the current main focus is 
on elevating striatal dopamine levels rather than trying to reconstruct the 
relatively long nigrostriatal pathway.  
Particular emphasis was attributed to the transplantation of fetal ventral 
mesencephalic tissue, which has resulted in the greatest clinical benefits in open 
labelled clinical trials. This approach was followed more recently  by a discussion 
of future perspectives of cell replacement for PD, with particular focus on stem 
cell based strategies. 
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Stem cells to treat Parkinson’s disease 
Stem cell research has the potential to significantly impact the development of 
disease-modifying treatments for Parkinson's disease, and considerable progress 
has been made in creating dopamine-producing cells from stem cells. The 
development of new cell models of Parkinson’s disease is a particularly 
promising area of stem cell research, as the current lack of progressive, 
predictive models of Parkinson’s disease remains a major barrier to drug 
development. Stem cells can help researchers as they can be utilized as cellular 
model to study pathogenesis of the disease particularly when it is possible to use 
cells taken from people living with the disease. Moreover, cellular models of 
Parkinson’s disease generated from stem cells could help the drug screening. 
 
 
 
 
Figure 14. Sources of stem cells for cell therapy approach in PD (from Jensen et al., 
2011).  
 
However, there are many challenges that need to be overcome before stem cell-
based cell replacement therapies for Parkinson’s disease become a reality. Work 
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is still needed to generate robust cells, in both quality and quantity, that can also 
survive and function appropriately in a host brain. Although ES (and more 
recently induced pluripotent stem cells, iPS) cells hold great potential, we do not 
yet know which stem cell type ultimately holds the greatest promise. Numerous 
studies using expanded and/or induced bone marrow-derived mesenchymal stem 
cells have been reported for animal models and yet only three clinical studies 
with intracerebral or intravasal application of these cells have been reported for 
PD patients. In two open label studies, subventricular application of both 
allogenic and autologous bone marrow-derived mesenchymal stem cells showed 
improvement of motor behavior as reflected by reduction of UPDRS ON and OFF 
scores in most but not all PD patients (Venkataramana et al 2010 and 2011). 
Furthermore, generation of iPS cells provides a new avenue for transplantation 
therapy as it can avoid immunorejection, a major complication in current 
transplantation medicine.  
 
Neural tissue transplants 
This cell therapy approach was pioneered in the 1970ies to develop methods for 
cell transplantation to the mammalian brain. Important contributions during this 
dynamic period included studies on the survival, integration and functional 
connectivity of fetal neuroblasts grafted to the CNS of adult rats, functional cell 
replacement in rodent models of Parkinson’s disease. 
 
In the mid-1980ies was performed a series of preclinical experimental studies 
that provided the experimental and methodological basis for the first open-label 
clinical trials that were initiated at Lund University Hospital in 1987. The results 
obtained in the Lund PD transplantation program have provided proof-of-principle 
that human fetal midbrain dopamine neurons can survive and function for many 
years (more than a decade) after transplantation to the striatum in patients with 
advanced Parkinson´s disease (1990-2005). The Lund PD transplantation 
program has over the ensuing decades been one of the leading programs in the 
development of restorative therapies in Parkinson´s disease. In 2008 were 
published results obtained from three independent groups reporting findings 
obtained from post-mortem tissue analyses in a total of eight subjects 
transplanted  with transplanting fetal nigral dopaminergic nerve cells, with the 
intention of replacing striatal dopamine. These studies showed that long-term 
clinical benefits in six individuals who survived 9–16 years after surgery is limited. 
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Moreover three of these subjects showed brain damages typical of Parkinson’s 
disease at autopsy, such as α-synuclein 
inclusions (Lewy bodies) (Mendez, I. et al. 2008; Kordower, J.H. et al. 2008; Li, 
J.-Y. et al. et al. 2008). The results se studies provide insights into the extent to 
which pathogenic factors in the host can influence the transplanted cells. 
The transplantation of stem cells or fetal nerve cells in the hopes of re-innervating 
the striatum in individuals with severe Parkinson’s disease was initially heralded 
as a breakthrough. But the results, which depend on a wide variety of factors—
age, disease duration, site of implantation, graft size and administration of 
immunosuppressive therapies—have been generally mixed. Moreover, graft 
recipients can experience adverse effects, including dyskinesias (Freed et al. 
2001;  Snyder, B.J. & Olanow, C.E.  2005). The additional risk factor of 
developing Lewy pathology open a strong issue about surgical replacement 
options, especially because we know that transplantation of fetal nerve cells does 
not alleviate neuronal dysfunction or neuronal loss at extranigral sites (Snyder, 
B.J. & Olanow, C.E.  2005) 
 
 
Embryonic stem cells 
For a long time ESCs have been considered the most promising source of cells 
for future cell replacement therapy in PD. However, ethical concerns regarding 
the use of human embryos and the possibility of immune rejection due to 
immunological incompatibility between patient and donor ESCs may limit their 
use. To overcome these problems scientists have worked on the development of 
pluripotent stem cells from adult somatic cells, involving genetic changes 
(reprogramming) of the somatic cell nucleus. Until recently, reprogramming of 
cells involved cloning of cells by somatic cell nuclear transfer, where the nucleus 
in an oocyte is replaced with the nucleus from an adult somatic cell (Wilmut et al. 
1997) or by fusion of an adult somatic cell with an ESC (Cowan et al. 2005). 
However, besides being both time consuming and technical difficult this kind of 
reprogramming still requires the use of human oocytes or ESCs and hence do 
not solve the ethical problems.  
 
Induced pluripotent stem cells 
In 2006, Takahashi and Yamanaka reported for the first time that it was possible 
to reprogram adult mouse fibroblasts to pluripotent stem cells by retroviral 
transduction with the four transcription factors Oct3/4, Sox2, c-Myc and Klf4, 
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which are highly expressed in ESCs (Takahashi and Yamanaka 2006). The 
resulting so-called induced pluripotent stem (iPS) cells share several properties 
with ESCs, including morphology, growth properties and pluripotency, defined by 
their ability to form teratomas in vivo and differentiate into distinct cell types of all 
three germ layers, but they are not identical to ESCs when it comes to epigenetic 
status (Deng et al. 2009) and gene expression (Chin et al. 2009). In addition, the 
original iPS cells failed to generate postnatal chimeras and contribute to the 
germline (Takahashi and Yamanaka 2006), but refinement of the method for 
selection of iPS cells has already solved these issues and moreover, the 
resulting iPS cells are even more similar to ECSs at the epigenetic level (Okita, 
Ichisaka, and Yamanaka 2007; Maherali et al. 2007; Meissner, Wernig, and 
Jaenisch 2007). Shortly after these initial studies in mice, iPS cells were derived 
from human fibroblasts using slightly different combinations of genes (Takahashi 
et al. 2007; Yu et al. 2007) and since then, iPS cells have been generated from a 
number of different cell types and species (Masip et al. 2010). 
 
The similarities of iPS cells to ESCs, and the fact that these cells can be 
generated from the patient’s own cells, make them very attractive candidates for 
cell-based therapy. Wernig and collegues reported upon transplantation into the 
fetal mouse brain, iPS derived neural precursor cells extensively differentiate into 
glia and neurons (Werning et al 2001). Functional recovery was observed after 
transplantation of iPS-derived midbrain dopamine neurons into the adult brain of 
Parkinsonian rats. Risk of tumor formation from grafted cells was minimized by 
the separation of contaminating pluripotent cells and committed neural cells using 
fluorescence-activated cell sorting. Encouraging data from rodent studies then 
prompted subsequent assessment in a primate model. Kikuchi and co-workers 
observed that human iPS-derived neural progenitor cells grafted in the brain of a 
primate PD model survived as dopaminergic neurons for as long as six months, 
implying the therapeutic potential of human iPS cells (Kikuki et al. 2012). Direct 
reprogramming of mouse and human fibroblasts into induced neural stem cells 
(iNSCs) has been proven feasible with a single factor, Sox2. iNSCs express NSC 
markers and resemble wild-type NSCs in their morphology, self-renewal, ability to 
form neurospheres and differentiate into several types of mature neurons as well 
as astrocytes and oligodendrocytes, indicating multipotency. Importantly, 
implanted iNSCs can survive and integrate in mouse brains without tumorigenic 
potential. Moreover, the  reprogramming method used in this work allowed 
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shortening of the duration for neuronal cell creation from fibroblasts (Ring et al 
2012). 
 
However, before iPS cells can be used in the clinic there are several issues that 
need to be resolved. First, it is extremely important to optimize the procedure for 
reprogramming of the somatic cells. As described above, many groups have 
generated iPS cells by use of retroviral vectors. Since retrovirus integrates 
randomly in the DNA it may alter the differentiation potential or even induce 
malignant transformation of the iPS cells. Moreover, most research groups have 
used c-Myc as one of the reprogramming factors and since c-Myc is a proto-
oncogene, its reactivation could give rise to transgene-derived tumor formation. 
In one study 20% out of 121 mice derived from an iPS cell line developed tumors. 
In these tumors, retroviral expression of c-Myc, but not Oct3/4, Sox2, or Klf4 was 
reactivated (Okita, Ichisaka, and Yamanaka 2007). Hence, recent studies have 
focused on developing safer reprogramming strategies, for example, by 
generation of iPS cells without using the c-Myc oncogene. In 2008, Nakagawa et 
al. generated iPS cell lines from both mouse and human fibroblasts without the 
use of c-Myc. They found that it was possible to generate cells expressing ESC 
markers, and that the induction of the fibroblasts to iPS cells was more specific, 
since a lower number of non-iPS cells were generated. However, efficiency of the 
generation process was substantially reduced with the omission of c-Myc. They 
also examined the tumourigenicity in mice derived from these cells and found 
that omission of the c-Myc retrovirus significantly reduced the risk of 
tumorigenicity in chimeras (Nakagawa et al. 2008). Other studies have also 
examined different combinations of transcription factors, and of the original four 
transcription factors, Oct3/4 is the only one that cannot be replaced by other 
transcription family members and have been required in every reprogramming 
strategy in both mouse and human cells. Other strategies have been to generate 
iPS cells using integration systems such as plasmids (Kaji et al. 2009) and 
transposons (Woltjen et al. 2009), which allow removal of these systems after 
reprogramming. Moreover, iPS cells have also been generated without genomic 
integration using nonintegrative adenoviral vectors (Zhou and Freed 2009; 
Stadtfeld et al. 2008), repeated plasmid transfection with or without the use of 
small molecules (Okita et al. 2010; Okita et al. 2008; Yu et al. 2009) and just 
addition of recombinant proteins (Zhou et al. 2009; Kim et al. 2009). Although, 
these methods are not yet as efficient as the retroviral approach, they have 
clearly shown that random DNA mutagenesis is not a requirement for 
Carelli S. R09272 
 
40 
reprogramming and give hope for the development of clinically applicable iPS 
cells free of viruses and transgenic integration.  
 
Interestingly, a recent publication have shown a method for direct reprogramming 
of fibroblasts into neurons, avoiding generation of undifferentiated cells and their 
following differentiation (Vierbuchen et al. 2010). They started from a pool of 
nineteen neural-lineage specific transcription factors and identified a combination 
of only three factors (Mash1, Brn2 and Myt1l) that were sufficient to convert 
mouse fibroblasts into functional neurons in vitro. Such induced neurons clearly 
have some advantages to iPS cells, since they avoid generation of pluripotent 
cells that can give rise to tumors. In this study the induced neurons mainly gave 
rise to GABAergic neurons after differentiation, but their regional identity is still 
unclear (Vierbuchen et al. 2010). This strategy offers new perspectives to the 
reprogramming field and future studies need to determine if certain cell types are 
more useful in generation of specific cells for replacement strategies and if it is 
necessary to reprogram cells all the way back to pluripotent stem cells. 
 
 
Table 2. Overview of advantages and disadvantages of different types of stem cells for cell 
replacement therapy for Parkinson Disease (from Jensen et al 2011). 
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Therapeutic molecules released by stem cells 
 
Instead of acting as a source of cells for neuronal replacement an alternative use 
of stem cells for transplantation is as so-called “cell factories” releasing 
neurotrophic and neuroprotective factors. Several neurotrophic factors have been 
shown to stimulate survival and/or differentiation of nigral dopaminergic neurons 
in vitro and in vivo (Evans and Barker 2008; Levy et al. 2005). Among neurtrophic 
factors, GDNF and some of the GDNF family members have shown the greatest 
promise as therapeutic agents for PD. Several studies have shown that GDNF 
can protect against nigrostiatal lesions in animal models. For instance, 
intravenous administration of MSCs overexpressing GDNF in mice before 
lesioning with MPTP has been shown to protect dopaminergic neurons in the 
substantia nigra as well as their striatal fibers (Park, Eglitis, and Mouradian 
2001). In agreement with this observation, another study has shown that GDNF-
producing mouse NSCs transplanted into the mouse striatum 16 days prior to 6-
OHDA lesioning could prevent death of dopaminergic neurons and resulted in a 
reduced behavioral impairment (Akerud et al. 2001). A similar protective effect 
was found by overexpressing Neurturin, another member of the GDNF family, in 
the same NSC line (c17.2 NSCs derived from the mouse cerebellum) (Liu et al. 
2007). NSCs are considered very suitable for ex vivo gene delivery, since they 
can be cultured, differentiated into specific neuronal subtypes, transduced and 
selected for subsequent transplantation to the brain where they can migrate and 
extend projections. Human NCSs genetically modified to overexpress GDNF in 
an inducible way have been shown to express GDNF for up to 3 month in the 
brains of rodents and aged primates (Behrstock et al. 2006). 
Furthermore, transplantation of these cells after a partial lesion of the dopamine 
system resulted in increased host dopamine neuron survival and fiber outgrowth. 
MSCs are also very suitable as neuroprotective cells through secretion of 
neurotrophic factors and furthermore, these cells can easily be harvested from 
the patient’s own bone marrow in order to avoid immune rejection. Along this line, 
Sadan et al. (2009) have recently developed a protocol to induce MSCs into 
neurotrophic factor-secreting cells, especially producing GDNF and BDNF 
without genetic modification of the cells. 
Another way to overcome problems of host immunoresponses when using 
allografts, is the development of new materials to encapsulate transplanted cells, 
thereby serving as a biological shield to prevent immune rejection and eliminate 
the need for immunosuppression. The encapsulating material should allow 
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inward diffusion of nutrients to the transplanted cells and at the same time permit 
outward secretion of trophic factors. Besides protection from the host immune 
system, these capsules have the advantage that they can be removed for safety 
reasons or for renewal of cells. Several studies have reported successful delivery 
of GDNF from encapsulated cells (Kishima et al. 2004; Tseng et al. 1997; Ahn et 
al. 2005). Kishima et al. (2004) found a transient recovery in motor function after 
intraventricular infusion of encapsulated GDNF-producing cells in MPTP lesioned 
baboons, however no neuroprotection against the toxin was found. The lack of 
neuroprotective effect may be due to the intraventricular placement of the 
capsules resulting in inefficient passage of GDNF to the striatum, thus better graft 
sites should be used. Furthermore, they reported GDNF release and survival of 
encapsulated cells for more than 1 year after transplantation (Kishima et al. 
2004). 
Delivery of neurotrophic factors by co-grafted genetically modified stem cells or 
cell lines may also serve as a useful tool for stimulation of functional integration 
and protection of grafted dopaminergic neurons from any source. In one study, 
Ahn et al. (2005) tested such a strategy by co-grafting an encapsulated cell line 
overexpressing GDNF with human fetal mesencepahlic tissue into 6-OHDA 
lesioned rats, leading to increased fiber outgrowth in areas between the capsules 
and the grafts. This result indicates that continuous delivery of GDNF or other 
important neurotrophic factors via encapsulated genetically modified cells could 
further optimize neural transplantation as a therapy for PD. 
 
 
2.11 Post- Mortem Neural Precursors Cells 
 
In 2010 we were able to isolate and characterize  adult neural stem cells from the 
mouse subventricular zone (SVZ) at different time after animal killing (Marfia et 
al., 2011). The isolation of ischemia-resistant neural precursors supplied cells 
with properties different from NPCs, and able to survive in the not favorable 
environment of the traumatically injured central nervous system (Molcanyi et al., 
2007; Popovich et al., 2003; Marfia et al 2011). This new type of neural stem 
cells were called Post-Mortem Neural Precursor Cells (PM-NPCs). Their 
proliferation is similar to that of NPCs obtained at killing time (T0) (Gritti et al., 
1996; Marfia et al., 2011) and was investigated by population analyses. Post-
mortem NPCs (PM-NPCs) proliferate in response to the exposure to bFGF and 
EGF, and formed typical neurospheres identical to those formed  by NPCs 
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obtained from fresh tissue (Figure 15). Under these conditions, less than 1% of 
the total cells plated survived, and began to divide, until a spherical cluster of 
cells was formed. We observed continuous growth over 1 year in presence of 
EGF and FGF-2, and the rate between the different types of PM-NPCs groups 
and T0 NPCs was not significantly different (Figure 15). The capability to 
generate neurospheres was also investigated. The total number of neurospheres 
generated within 7 days of cell seeding was calculated, and the average was 
plotted (Figure 15).   
 
 
 
Figure 15. PM-NPCs perpetuation and population analysis. The perpetuation and 
continuous growth properties of PM-NPCs are comparable of T0 NPCs. Cells were plated 
in growth medium at the density of 10,000 cells/cm2. PM-NPCs population analysis was 
performed by counting the number of neurospheres generated after 10 days of culture. It 
is represented the number of neurospheres generated by 3000 cells plated in a single 
well.  
 
After removal of growth factors and addition of serum and adhesion molecules, 
PM-NPCs and NPCs attach to the dish and begin the differentiation process into 
neurons, astrocytes, and oligodendrocytes. The extent of the differentiation was 
evaluated by monitoring the number of cells expressing -tubulin III, MAP-2, 
GFAP, and O4 antigens 7 days after differentiation induction (Figure 16) 
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Figure 16. Differentiation features of PM-NPCs. After removal of growth factors, PM-
NPCs and NPCs neurospheres readly differentiates into -tubulin III - and MAP2 positive 
neurons, and O4 labelled oligodendrocytes with NG2- positive precursors. 
 
The differentiation of PM-NPCs yields about 33 % tubulin III- and 36% of 
MAP2- positive cells compared to 10-12% of classical neural precursors. 
Moreover it has been shown that differentiated PM-NPCs show higher HIF-
1activation, express both EPO and EPO-R,  and active voltage-dependent 
Ca++ channels (Marfia et al, 2011). Such a higher differentiation requires the 
functionality  of mTOR and MAPK systems and is prevented by exposure to anti-
EPO and anti- EPO-R antibodies (Figure 17; Marfia et al 2011). 
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Figure 17. EPO-dependent differentiation of SVZ-neural progenitors and PM-NPCs 
into neurons and MAP-kinase ERK and mTOR involvement.   
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3. Aim of the Study   
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Parkinson's disease (PD) is a common neurodegenerative disorder— 
synucleinopathy—with a prevalence of 160/100 000 in Western Europe rising to ∼4% 
of the population over 80 (http://www.epda.eu.com). With an ageing population, the 
management of PD is likely to prove an increasingly important and challenging aspect 
of medical practice for neurologists and general physicians. The pathological hallmark 
of PD is cell loss within the substantia nigra particularly affecting the ventral component 
of the pars compacta. While there are some effective pharmacological treatments for 
patients with PD these strategies are mainly symptomatic and aimed at increasing 
dopamine levels in the degenerating nigrostriatal system.  Existing drugs are limited in 
their relief and decrease in effectiveness as PD progresses.  
Cell replacement therapy for treatment of PD has been focused on the hypothesis that 
immature dopaminergic neurons, after transplantation and functional integration into 
the striatum, can restore dopaminergic neurotransmission and exert long-lasting effects 
on motor symptoms. Based on data obtained from pre-clinical research approaches, 
the current main focus is on elevating striatal dopamine levels rather than trying to 
reconstruct the relatively long nigrostriatal pathway. Particular emphasis was attributed 
to the transplantation of fetal ventral mesencephalic tissue, which has resulted in the 
greatest clinical benefits in open labelled clinical trials. This approach was followed 
more recently  by a discussion of future perspectives of cell replacement for PD, with 
particular focus on stem cell based strategies. The principal aim of this thesis work 
was to test the potential role of post mortem neural precursors cells (PM-NPCs) 
in terms of replacement therapy in a mouse model of Parkinson’s disease. PM-
NPCs are  a subclass of Sub Ventricular Zone (SVZ)-derived neural progenitors, 
capable of surviving many hours after donor death (Marfia et al.,  2011). The in vitro 
differentiation of these cells yields more neurons (about 30-40%) compared to NPCs 
isolated immediately after the animal sacrifice. With the aim to improve the monitoring 
of cells after transplantation, PM-NPCs was isolated from the SVZ of mice 
constitutively expressing the green florescent protein (GFP).   
Detailed Aims: 
 Isolation and characterization of GFP- PM-NPCs. To this proposal we will 
focus our attention to the transgenic mouse strain expressing green fluorescent 
protein (GFP) under the promoter C of the ubiquitin gene [C57BL/6-Tg(UBC-
GFP)30Scha/J]. Cells was isolated from the SVZ at 6 hours after the donor 
death. These cells was characterized for their growth features and capability to 
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aggregate into spheres (neuropheres). Moreover, the GFP PM-NPCs in vitro 
differentiation potential was investigated by means immunofluorescence 
approach, focusing on the expression of neural markers such as MAP-2 
(neurons), GFAP (astrocytes) and NG2 (oligodendrocytes).   
 
 GFP PM-NPCs transplantation in animal model of parkinson’s disease. As 
experimental model C57BL/J mice will be utilized and the parkinsonism was 
induced by means of the administration of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) following a specific paradigm: a first i.p. injection at 
36 mg/kg intraperiteoneally followed of a second injection of 20 mg/Kg i.p. after 
seven days. The effect of the neurotoxin on the motor behavior was evaluated 
by specific animals tests, such as horizontal, vertical grid tests and with stride 
length test. Furthermore, HPLC analyses was performed to measure 
catecholamines and their metabolites levels in order to corroborate the 
behavioral data. 
 
 
 Evaluation of GFP PM-NPCs in vivo effects. During the two weeks after 
transplantation the PM-NPCs effects was assessed by specific behavioral tests 
(see above for details). At the end of this observation period (two weeks) the 
animals was sacrificed, their brains was removed and specific areas (striatum, 
midbrain and cortex) was dissected. By using HPLC approach the 
catecholamines  and their metabolites levels were measured, in order to study 
the neurochemical changes. 
 
 Fate and distribution of GFP PM-NPCs after transplantation. These part of 
the project was developed by means of immunohistochemistry approach 
associated to confocal microscopy and was performed at the end of the animal 
observation period (two weeks). Investigating the GFP distribution in brain 
areas was assessed whether grafted cells were able to migrate beyond the 
striatum and to overtake the striatum margins reaching other brain areas. 
Moreover, through the analysis of neural markers expression (Nestin, MAP-2, 
GFAP, NG2 and NEUN) the in vivo fate of grafted PM-NPCs after  
transplantation was assessed.  
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4. Materials and Methods 
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4.1 Post-Mortem Neural Precursor Cells Derivation 
Post mortem neural precursors constitutively expressing green fluorescent 
protein were obtained from 2 month old C57 black mice carrying the transgene 
for green fluorescent protein  under the control of ubiquitin promoter C (C57BL/6-
Tg(UBC-GFP)30Scha/J; The Jackson Laboratories, Bar Harbor, Maine, USA).  
Adult C57BL/6-Tg(UBC-GFP)30Scha/J mice weighing 25-30 g (Charles River) 
were anesthetized by intraperitoneal injection of 4% chloral hydrate (0.1 ml/10 
gm body weight) and then killed by cervical dislocation. The cadavers were 
maintained at room temperature (25°C) for 6 hours. Their brains were removed 
after the indicated periods and the area encompassing the SVZ surrounding the 
lateral wall of the forebrain ventricle was dissected using fine scissors. Primary 
cultures and cultivation of NPCs, their differentiation and immunostaining were 
performed as previously described  (Bottai et al 2008; Gritti et al 1999).  
The cells were plated at 3500 cells/cm2 in the appropriate volume of the 
aforementioned medium in a 25 cm2 flask at 37 °C in a humidified 5% CO2 
atmosphere. 
4.2 PM-NPCs  perpetuation, population analysis and differentiation 
PM-NPCs Perpetuation of the culture 
Neural Precursors were plated in growth medium containing FGF2 and  EGF at the density of 
10,000 cells/cm2, 4-5 days of cell division gave rise to neurospheres (Gritti et al 1996; 1999). The 
total number of viable cells was assessed by trypan blue exclusion. This procedure was repeated 
every 4-5 days for up to 6 months.  
 PM-NPCs Population Analysis 
then, cultured for 4-5 days at 37 °C in a humidified 5% CO2 atmosphere. The assay was carried 
out in a  48 -well plate coated with polylysine or polyornithine, and the spheres formed after 4-5 
days were harvested and counted. At each passage neurospheres were harvested by 
centrifugation and mechanically dissociated by pipetting and cells were plated again. The 
logarithmic value of the total viable cell number was plotted against the day in vitro (days) since the 
beginning of the experiment. The experiment was performed three times in triplicate per each 
sample (Gritti et al 1996; 1999) and was repeated at passage 7, 15 and 30 without observing 
significant differences. 
Differentiation of the PM-NPCs 
Differentiation and expression of various epitopes were achieved within 7 days. Differentiation of 
PM-NPCs was achieved first of all plating the dissociated stem cells at the density of 40,000 
cells/cm2 in presence of adhesion molecules (Matrigel™) and bFGF (10ng/ml) for 48 hours, for the 
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other 5 days the growth factor was removed and foetal bovine serum (1% vol/vol) was added to the 
medium. Cells were characterized by immunocytochemical staining. 
The immunostaining was performed as follows, differentiated PM-NPCs were fixed with 4% 
paraformaldehyde in PBS for 10 minutes at room temperature, and, then, washed with PBS. The 
coverslips were incubated for 90 min at 37°C (or overnight at 4 °C) in PBS containing 10% normal 
goat serum (NGS), 0.3% Triton X-100, and the appropriate primary antibodies or antisera. After 
thorough washing with PBS and 10% NGS, cells were reacted for 45 minutes (room temperature) 
with secondary antibody Alexa Fluor 488 or 543 anti-mouse or rabbit (Invitrogen, Carlsbad, 
California). The cells were then counterstained with the DNA-binding dye 4'-6'-diamidino-2-
phenylindole (DAPI) (2 μg/ml in PBS) for 10 minutes at room temperature, twice washed in PBS 
followed. Coverslips containing the stained differentiated cells were mounted onto glass slides and 
examined under a fluorescence microscope (Leica, Wetzlar, Germany). Acquisition of the stained 
cells was performed using the image-analysis software (Leica, Wetzlar, Germany ) or by confocal 
microscope Leica SP2 microscope with He/Kr and Ar lasers (Leica, Wetzlar, Germany). Images 
were taken with a 40X objective lens and 1X zoom (Leica). In control experiments, primary 
antibodies were either omitted or replaced with equivalent concentrations of unrelated Ig of the 
same subclass. Moreover, in double labelling experiments, sections incubated with one primary 
antibody and two secondary anti-sera revealed no appreciable cross-reaction. Neural differentiation 
was assessed by immunocytochemistry with antibodies against: Nestin (monocl.1:100; 
Pharmingen, San Jose, CA, USA), β-tubulin III (monocl. 1:150; Sigma), microtubule-associated 
protein 2 (MAP2; monocl. 1:200; Sigma), Glial fibrillary acidic protein (GFAP; monocl. 1:400; 
Roche, Basel, CH), Tyrosine Hydroxylase (TH; monocl. 1:400; Chemicon),  
4.3 Cell count 
The quantification of positive cells to neural markers (see above) was performed, by confocal 
microscopy, after  specifical immunocytochemical staining following 7 days differentiation in culture. 
Briefly, cell counts were performed on a minimum of 9 independent fields (3 fields/3 
coverslips/treatment) of photomicrographs captured with 40X objective. Total counts of each neural 
markers immunoreactive cells were performed and the number of positive cells per culture was 
expressed as the percentage to the total cells. DAPI supplied the total number of cells being a 
nuclear staining. 
 
4.4 Experimental model 
Male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) were used for these experiments. 
Five weeks old mice, weighing 22-24 g, were housed individually and handled daily for 1 week prior 
to MPTP injection, in order to make them amenable to behavioral testing. All mice were maintained 
on standard environmental conditions (12:12 light/dark cycle; room temperature +21 °C) and given 
access to lab chow and water ad libitum. MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a 
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neurotoxin precursor to MPP+, which causes permanent symptoms of Parkinson's disease by 
destroying dopaminergic neurons in the substantia nigra of the brain. It has been used to study 
disease models in various animal studies. 
Injection of MPTP causes rapid onset of Parkinsonism, hence users of MPPP contaminated with 
MPTP will develop these symptoms. 
MPTP itself is not toxic, and as a lipophilic compound can cross the blood–brain barrier. Once 
inside the brain, MPTP is metabolized into the toxic cation 1-methyl-4-phenylpyridinium (MPP+) by 
the enzyme MAO-B of glial cells. MPP+ kills primarily dopamine-producing neurons in a part of the 
brain called the pars compacta of the substantia nigra. MPP+ interferes with complex I of the 
electron transport chain, a component of mitochondrial metabolism, which leads to cell death and 
causes the buildup of free radicals, toxic molecules that contribute further to cell destruction. 
Because MPTP itself is not directly harmful, toxic effects of acute MPTP poisoning can be mitigated 
by the administration of monoamine oxidase inhibitors (MAOIs) such as selegiline. MAOIs prevent 
the metabolism of MPTP to MPP+ by inhibiting the action of MAO-B, minimizing toxicity and 
preventing neural death. 
MPP+ has quite selective abilities to cause neuronal death in dopaminergic cells, it is presumed 
through a high-affinity uptake process in nerve terminals normally used to reuptake dopamine after 
it has been released into the synaptic cleft. The dopamine transporter moves MPP+ inside the cell. 
The resulting gross depletion of dopaminergic neurons has severe implications on cortical control 
of complex movements. The direction of complex movement is based from the substantia nigra to 
the putamen and caudate nucleus, which then relay signals to the rest of the brain. This pathway is 
controlled via dopamine-using neurons, which MPTP selectively destroys, resulting over time in 
parkinsonism. 
MPTP causes parkinsonism in primates including humans. Rodents are much less susceptible. 
Rats are almost immune to the adverse effects of MPTP. Mice were thought to only suffer from cell 
death in the substantia nigra (to differing degree according to the strain of mice used) but do not 
show Parkinsonian symptoms, however most of the recent studies indicate that MPTP can result in 
Parkinsonism-like syndromes in mice (especially chronic syndromes). It is believed that the lower 
levels of MAO-B in the rodent brain's capillaries may be responsible for this.  
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Figure 18. Scheme of MPTP toxicity in dopaminergic neurons 
 
 
Six weeks old C5BL/6J mice were subjected of a first intraperitoneal injection of MPTP (36 mg/kg). 
Motor disfunctions were evaluated (see below) every 2 days for the following 7 days, then animals 
were subjected to a second injection (20mg/kg).  
 
 
4.5 Cells injection  
After 3 days from the second MPTP injection (day 10), cells were injected by stereotaxic surgery 
into the striatum (1x105 cells in 5 μL). Control group was injected with 5 μL of sterile PBS. 
Coordinates, in relation to bregma, were: 0.1 mm posterior, 2.4 mm mediolateral, and 3.6 mm 
dorsal (Cui et al., 2010). 
  
4.6 Animal care and behavioral evaluation.  
After transplantation, animals were looked after for 5 days, subjected to antibiotic therapy 
(Gentamicin 1mg/ml, SIGMA) and rehydrated with saline solution and Vitamin C. Animals weight 
and urine pH were checked periodically until the end of the experiments. The recovery of motor 
dysfunctions, before and after cells transplantation, was investigated by means of horizontal and 
vertical grid tests. 
Horizontal grid test. Once the mouse firmly grabbed on the grids (12 cm2) with all four paws, the 
apparatus was inverted and the animal was videotaped for a maximum duration of 30’’. With each 
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weight-bearing step, the paw may fall or slip between the wire. This was recorded as a foot fault. 
The total number of steps (movement of each forelimb) that the mouse used to cross the grid was 
counted, and the total number of foot faults for each forelimb were recorded (Tillerson et al., 
2002, Tillerson and Miller, 2003 and Meredith and Kang, 2006). 
Vertical grid test. In this test the mouse was placed 3 cm from the top of the apparatus (8cm x 
55cm x 5cm), facing upward, and was videotaped while it turned around and climbed down. The 
score reported was the time required to climb ( Kim S. T. et al., 2010). 
 
4.7 HPLC analysis of catecholamines 
1. Homogenize tissue samples in 600 μL of ice-cold 0.1 mol/L perchloric acid containing 10 pg/μL of 
dihydroxybenzylamine (DBA) as the internal standard;  
2. Keep an aliquot of homogenate for the protein assay by using Bradford method (Bradford, 1976) 
3. Centrifuge homogenates and use the supernatant for the determination of levels of monoamines 
and their metabolites by reverse-phase HPLC coupled with an electrochemical detector.  
One liter of mobile phase contained 10.35 g (75 mol/mL) of sodium dihydrogen orthophosphate, 
0.505 g (2.5 mol/mL) of heptane sulfonic acid, 25 mol/μL EDTA, 100 μL of triethylamine, and 
200 mL of acetonitrile, and the final pH was adjusted to 3.00 with phosphoric acid. We used a C18 
reverse-phase column (Inertsil ODS-3, 4.6 × 250 mm, 5 μm; Beckman, San Ramon, CA, USA). 
The mobile phase (filtered and degassed) was delivered at a flow rate of 1.2 mL/min; the applied 
potential was set to −0.10 V for detector 1 and +0.30 V for detector 2.  
For catecholamine assays, a standard curve was prepared using known amounts of DA and its 
metabolites dissolved in 0.1 mol/L perchloric acid containing a constant amount (10 pg/μL) of the 
internal standard (DBA), as used for tissue samples. The standard curve for each compound (DA 
or its metabolites) was calculated using regression analysis of the ratios of the peak areas 
(compound area/DBA area) for various concentrations of each compound recorded at the reducing 
electrode. An analogous regression analysis was performed for the oxidizing electrode. For DA and 
its metabolites, results are expressed as the mean ± SEM of eight animals per group. (Viaggi et 
al.,2009) 
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4.8 Real Time RT-PCR analyses 
Real-time RT-PCR quantities the initial amount of the template most specifically, sensitively and 
reproducibly, and is a preferable alternative to other forms of quantitative RT-PCR that detect the 
amount of final amplified product at the end-point (Freeman WM, 1999). Real-time PCR monitors 
the fluorescence emitted during the reaction as an indicator of amplicon production during each 
PCR cycle as opposed to the endpoint detection (Higuchi R et al., 1993), eliminating post-PCR 
processing of PCR products. This helps to increase throughput and to reduce the chances of 
carryover contamination. In comparison to conventional RT-PCR, real-time PCR also offers a much 
wider dynamic range of up to 107-fold (compared to 1000-fold in conventional RT-PCR). The real-
time PCR system is based on the detection and quantitation of a fluorescent report (Livak KJ et al., 
1995). This signal increases in direct proportion to the amount of PCR product in a reaction. By 
recording the amount of fluorescence emission at each cycle, it is possible to monitor the PCR 
reaction during exponential phase where the first significant increase in the amount of PCR product 
correlates to the initial amount of target template. The higher the starting copy number of the 
nucleic acid target, the sooner a significant increase in fluorescence is observed. Currently four 
different chemistries, TaqMan®, Molecular Beacons, Scorpions® and SYBR® Green (BIO-RAD), 
are available for real-time PCR. All of these chemistries allow detection of PCR products via the 
generation of a fluorescent signal.  
 
       Figure 19. Real time RT-PCR curves and Ct values. 
 
TaqMan probes, Molecular Beacons and Scorpions depend on Förster Resonance Energy Transfer 
(FRET) to generate the fluorescence signal via the coupling of a fluorogenic dye molecule and a 
quencher moiety to the same or different oligonucleotide substrates. SYBR Green is a fluorogenic 
dye that exhibits little fluorescence when in solution, but emits a strong fluorescent signal upon 
binding to double-stranded DNA. The threshold cycle or Ct value (Figure 19) is the point when the 
system begins to detect the increase in the signal associated with an exponential growth of PCR 
product during the log-linear phase. This phase provides the most useful information about the 
reaction and the slope of the log-linear phase is a reflection of the amplification efficiency. The 
efficiency (Eff) of the reaction can be calculated by the formula: Eff=10(-1/slope) – 1. The efficiency of 
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the PCR should be 90 - 100% (–3.6 > slope > –3.1). A number of variables can affect the efficiency 
of the PCR. These include length of the amplicon, secondary structure and primer quality. The Ct is 
an important parameter for quantitation. The higher the initial amount of genomic DNA, the sooner 
accumulated product is detected in the PCR process, and the lower is the Ct value. The threshold 
should be placed above any baseline activity and within the exponential increase phase. Some 
software allows determination of the cycle threshold (Ct) by a mathematical analysis of the growth 
curve. This provides better run-to-run reproducibility. Two strategies are commonly employed to 
quantify the real-time RT-PCR data: the standard curve method (absolute quantification) and the 
comparative Ct method (relative quantification). 
In the standard curve method, a standard curve is first constructed from an RNA of known 
concentration. This curve is then used as a reference standard for extrapolating quantitative 
information for mRNA targets of unknown concentrations, thus generating absolute copy number 
data. In addition to RNA, other nucleic acid samples can be used to construct the standard curve, 
including purified plasmid dsDNA, in vitro generated ssDNA or any cDNA sample expressing the 
target gene. Spectrophotometric measurements at 260 nm can be used to assess the 
concentration of these DNAs, which can then be converted to a copy number value based on the 
molecular weight of the sample used. However, cDNA plasmids are the preferred standards for 
standard curve quantitation. The comparative Ct method involves comparing the Ct values of the 
samples of interest with a control or calibrator such as a non-treated sample or RNA from normal 
tissue. The Ct values of both the calibrator and the samples of interest are normalized to an 
appropriate endogenous housekeeping gene. The comparative Ct method is also known as the 2–
ΔΔCt method [Livak and Schmittgen, 2001], where ΔΔCt = ΔCt,sample - ΔCt,reference. ΔCt,sample is the Ct 
value for any sample normalized to the endogenous housekeeping gene and ΔCt, reference is the Ct 
value for the calibrator also normalized to the endogenous housekeeping gene. For the ΔΔCt 
calculation to be valid, the amplification efficiencies of the target and the endogenous reference 
must be approximately equal. This can be established by looking at how ΔCt varies with template 
dilution. If the plot of cDNA dilution versus delta Ct is close to zero, it implies that the efficiencies of 
the target and housekeeping genes are very similar. This quantification method is described in the 
Applied Biosystems User Bulletins #2 and #5. Relative gene expression comparisons work best 
when the expression of the chosen internal control is abundant and remains constant among the 
samples. By using an invariant endogenous control as an active reference, quantitation of an 
mRNA target can be normalised for differences in the amount of total RNA added to each reaction. 
For this purpose, the most common choices are 18S RNA, GAPDH (glyceraldehyde-3-phosphate 
dehydrogenase) and -actin.  
 Real-time PCR requires an instrumentation platform that consists of a thermal cycler, a computer, 
optics for fluorescence excitation and emission collection, data acquisition, and analysis software. 
These machines, available from several manufacturers, differ in sample capacity (some are 96-well 
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standard format, others process fewer samples or require specialized glass capillary tubes), 
method of excitation (some use lasers, others broad spectrum light sources with tuneable filters), 
and overall sensitivity.  
RNA Extraction 
Brain areas were obtained from C57black mice and the experiments were performed on frontal 
cortex, striatum and midbrain. Total RNA was isolated by using TRI Reagent® (SIGMA) in 
accordance with the manufacturer’s instructions. In briefly, the procedure used was the following: 
 Add 1 ml of TRI Reagent directly on the culture dish. After addition of the reagent, the tissue 
homogenate should be passed several times through a pipette to form a homogenous lysate.   
 Phase Separation: To ensure complete dissociation of nucleoprotein complexes, allow samples to 
stand for 5 minutes at room temperature. Add 0.2 ml of chloroform per ml of TRI Reagent used. 
Cover the sample tightly, shake vigorously for 15 seconds, and allow to stand for 15 min at room 
temperature. Centrifuge the resulting mixture at 12,000 x g for 15 minutes at 4°C.  
Centrifugation separates the mixture into 3 phases: a red organic phase (containing protein), an 
interphase (containing DNA), and a colourless upper aqueous phase (containing RNA). 
 Transfer the aqueous phase to a fresh tube and add 0.5 ml of isopropanol per ml of TRI Reagent 
used in Sample Preparation and mix. Allow the sample to stand for 10 min at room temperature. 
Centrifuge at 12,000 x g for 10 min at 4°C. The RNA precipitate will form a pellet on the side and 
bottom of the tube. 
 Remove the supernatant and wash the RNA pellet by adding 1 ml of 75% ethanol per 1 ml of TRI 
Reagent used in Sample Preparation. Vortex the sample and then centrifuge at 7,500 x g for 5 min 
at 4°C. 
 Briefly dry the RNA pellet for 5–10 minutes by air-drying. Do not let the RNA pellet dry completely, 
as this will greatly decrease its solubility. Add an appropriate volume of 0.5% SDS water, or to the 
RNA pellet. To facilitate dissolution, mix by repeated pipetting with a micropipette at 55–60 °C for 
10 min. 
The ratio between A260/A280 was calculated to verify RNA purity. 100 ng/sample was used for 
cDNA synthesis.  
 
Degradation of genomic DNA and reverse transcription-PCR (RT-PCR) 
The degradation of contaminating genomic DNA from RNA samples was performed with DNase I 
(RNase-free) (New England BioLabs) according to manufacturer’s instructions. In briefly, the 
procedure used was the following: 
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 Resuspend 1 µg RNA in 1X DNase I Reaction Buffer to a final volume of 10 µ. 
 Add 1 unit of DNase I, mix thoroughly and incubate at 370C for 10 min.  
 Add 0.5 M EDTA to a final concentration of 5 mM. EDTA should be added to a final concentration of 5 
mM to protect RNA from being degraded during enzyme inactivation. 
 Heat inactivate at 750C for 10 min. 
The synthesis of single-strand cDNA was carried out on 1 μg of RNA template, using iScript™ 
Reverse Transcription Supermix for RT-qPCR (BIO-RAD) following the manufacturer’s instructions. 
 
Component Volume per reaction 
5X iScript reverse transcription supermix 4 µl 
RNA template (1 µg total RNA) 11 µl 
Nuclease-free water 5 µl 
Total volume 20 µl 
 
Reaction protocol: 
 
Priming 5 min at 250C 
Reverse transcription 30 min at 420C 
RT inactivation 5 min at 850C 
 
Retrotrascription samples are stored at -20°C, until their use for real time RT-PCR. 
In our experimental conditions, Real-time PCR was performed in an MJ Opticon 2 using iQ™ 
SYBR Green supermix (BIO-RAD) following the manufacturer’s instructions. 18S rRNA was used 
as reference housekeeping gene for normalization. We performed an analysis using the ΔΔCt, this 
procedure can be used since we have determined previously that the replication efficiencies 
(slopes of the calibration or standard curves) for the genes of interest and housekeeping gene are 
very close. All the amplification reactions were performed in duplicate. The primers were designed 
using Oligo Perfect® Designer Software (INVITROGEN). The nucleotide sequences of the primers 
were: 
Gene Name Forward primer Reverse primer 
18S TTTCGGAACTGAGGCCATGATTAAG AGTTTCAGCTTTGCAACCATACTCC 
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Table 3. The nucleotide sequences of the primers used for the experiments  
 
 
 
 
 
 
 
 
 
 
IL1beta GGCAACTGTTCCTGAACTCAACTGTG
AAAT 
CAGGTAGCTGCCACAGCTTCTCCAC
AGCCA 
IL1alpha  ATGGCCAAAGTTCCTGACTTGTTTGA
AGAC 
GTTGCTTGACGTTGCTGATACTGTCA
CCCG 
IL6 TCCAGTTGCCTTCTTGGGACTGATGC
TGGT 
AGTTTCAGATTGTTTTCTGCAAGTGC
ATCA 
IL8 GCTCCTGCTGGCTGTCCTTAACCTAG
GCAT 
ATTGGGCCAACAGTAGCCTTCACCC
ATGGA 
IL10 CCTGGCTCAGCACTGCTATGCTGCC
TGCTC 
AAGTAACCCTTAAAGTCCTGCATTAA
GGAG 
IL15 CCATCTCGTGCTACTTGTGTTTCCTT
CTAA 
GAAAGCAGTTCATTGCAGTAACTTTG
CAAC 
TNFalpha GACGTGGAACTGGCAGAAGAGGCAC
TCCCC 
GAGGCCATTTGGGAACTTCTCATCCC
TTTG 
NGF CTCAGCAGGAAGGCTACAAGA TACAGGCTGAGGTAGGGAGG 
BDNF     ACTACCAAAGCCACAAGGCA GCTGATCCTCATGCCAGTCA 
GDNF GGGATGTCGTGGCTGTCTGCCTGGT
GTTGC 
GCATATTGGAGTCACTGG
TCAGCGCGAAGG 
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Real Time RT PCR conditions 
Amplification reactions were performed in 96-well standard plate. Each sample was analysed in 
duplicate. Reaction mix for all primers was prepared adding 1 l of cDNA sample (dilution 1:10) to 
the following mix: 
 0.6 μl of primer forward (10 M) 
 0.6 μl of primer reverse (10 M) 
 5.3 μl of Dnase and Rnase free water 
 7.5 μl of 2X iQ™ SYBR Green supermix  
 
Amplification conditions were:  
 95°C for 40 sec 
 58°C for 40 sec 
 72°C for 1 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 cycles 
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4.9 Immunohistochemistry 
 
Confocal microscopy 
Confocal microscopy offers several advantages over conventional optical 
microscopy, including controllable depth of field, the elimination of image 
degrading out-of-focus information, and the ability to collect serial optical sections 
from thick specimens. The key to the confocal approach is the use of spatial 
filtering to eliminate out-of-focus light or flare in specimens that are thicker than 
the plane of focus. In recent years, there has been a tremendous explosion in the 
popularity of confocal microscopy, due in part to the relative ease with which 
extremely high-quality images can be obtained from specimens prepared for 
conventional optical microscopy. In a conventional wide field microscope, the 
entire specimen is bathed in light from a mercury or xenon source, and the image 
can be viewed directly by eye or projected onto an image capture device or 
photographic film. In contrast, the method of image formation in a confocal 
microscope is fundamentally different. Illumination is achieved by scanning one 
or more focused beams of light, usually from a laser or arc-discharge source, 
across the specimen. This point of illumination is brought to focus in the 
specimen by the objective lens, and laterally scanned using some form of 
scanning device under computer control. The sequences of points of light from 
the specimen are detected by a photomultiplier tube (PMT) through a pinhole (or 
in some cases, a slit), and the output from the PMT is built into an image and 
displayed by the computer (Figure 23). Although unstained specimens can be 
viewed using light reflected back from the specimen, they usually are labelled 
with one or more fluorescent probes.  
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Figure 20. principles of confocal microscopy 
 
Specimen Preparation and Imaging  
The procedures for preparing and imaging specimens in the confocal microscope are largely 
derived from those that have been developed over many years for use with the conventional wide 
field microscope. In the biomedical sciences, a major application of confocal microscopy involves 
imaging either fixed or living cells and tissues that have usually been labelled with one or more 
fluorescent probes. A large number of fluorescent probes are available that, when incorporated in 
relatively simple protocols, specifically stain certain cellular organelles and structures. Among the 
plethora of available probes are dyes that label nuclei, the Golgi apparatus, the endoplasmic 
reticulum, and mitochondria, and also dyes such as fluorescently labelled phalloidins that target 
polymerized actin in cells. Regardless of the specimen preparation protocol employed, a primary 
benefit of the way in which confocal microscopy is carried out is the flexibility in image display and 
analysis that results from the simultaneous collection of multiple images, in digital form, into a 
computer. 
 
Critical aspects of Confocal microscopy 
Quantitative three-dimensional imaging in fluorescence microscopy is often complicated by 
artefacts due to specimen preparation (e.g. autofluorescence problems, retractile structures 
presence, presence or absence of highly stained structures, immersion oil, coverslip thickness 
etc.), controllable and uncontrollable experimental variables or configuration problems with the 
microscope (e.g. optical component alignment, objective magnification, bleaching artefacts, 
aberrations, quantum efficiency, and the specimen embedding medium). 
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In our experimental conditions, the immunofluorescence experiments were assessed by confocal 
microscopy TSC SP2 Leica. 
Tissue collection and processing, histology and immunohistochemistry 
 
At the end of the experimental period, animals were anesthetized by i.p. injection of cloralium 
hydrate 4% in distilled water, and perfused with 4% paraformaldehyde in phosphate buffer (PB) 0.1 
M pH 7.4 by transcardial perfusion. Brains were post-fixed overnight in the same fixative, 
cryoprotected with 30% sucrose, quickly frozen, stored at -80°C and sectioned by means of a 
cryostat (Leica). Cryostat sections (10 µm) were collected onto glass slides and processed for 
immunocytochemistry. Sections were rinsed with PBS, treated with blocking solution and incubated 
with primary antibodies overnight at 4°C. After treatment with primary antibodies, the sections were 
washed with PBS and incubated with appropriate secondary antibodies (Alexa Fluor® 546 or/and 
Alexa Fluor® 488, Molecular Probes®, Invitrogen, Life Technologies Italia, Monza, Italy) for 2 hours 
at room temperature. Sections were washed in PBS, nuclei were stained with DAPI (Hoechst 
1/1000) and then  mounted using the FluorSave Reagent (Calbiochem, Merck Chemical, 
Darmstadt, Germany) and analyzed by confocal microscopy. In control determinations, primary 
antibodies were omitted and replaced with equivalent concentrations of unrelated IgG of the same 
subclass. The following primary antibodies were used: Microtubule-Associated Protein 2 (MAP2) 
(1:300; Chemicon), Glial Fibrillary Acidic Protein (GFAP) (1:400; Covance), β-Tubulin III (1:150; 
Covance), Choline Acetyltransferase (ChAT) (1:1000; Chemicon. For immunofluorescence, the 
following secondary antibodies were used:  488 goat-anti-mouse IgG (1:200; Alexa), 488 donkey-
anti-rabbit IgG (1:200; Alexa), 546 goat-anti-rabbit IgG (1:200; Alexa), 546 goat-anti-chicken IgG 
(1:200; Alexa). Images were taken using Leica SP2 confocal microscope with He/Kr and Ar lasers 
(Heidelberg, Germany). In negative control experiments, primary antibodies were replaced with 
equivalent concentrations of unrelated IgG of the same subclass. The quantification of positive cells 
was performed by considering on a minimum of 9 independent fields (3 fields/3 
coverslips/treatment) of photomicrographs captured with 20X objective. Total count of each 
markers immunoreactive cells was performed and the number of positive cells expressed as the 
percentage to the total cells. DAPI supplied the total number of cells being a nuclear staining.  
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4.10 SDS Page, Western blotting and protein detection 
Protein sample preparation for electrophoresis 
50-75 μg of protein samples (cell lysate or tissue homogenate), previously TCA precipitated or not, 
are combined with Novex Tris-Glycine SDS sample buffer 2X (Invitrogen) containing 5% 2-β 
mercaptoethanol (70mM) in a microcentrifuge tube. In the case of TCA precipitation, Tris buffer is 
sometimes added to adjust pH if TCA residues are still present in sample resuspension. Many 
proteins have significant hydrophobic properties and may be tightly associated with other 
molecules, such as lipids, through hydrophobic interaction. Heating the samples to at least 60°C 
shakes up the molecules, allowing SDS to bind the hydrophobic regions and completing the 
denaturation. Thus, the samples are boiled for 5-10’ to fully denature the proteins and kept at room 
temperature until they are ready to load onto the gel. Molecular weight marker (5μl) (Bio-Rad) is 
aliquoted in a separate tube and boiled for 1 min. 
SDS Page 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) is probably the most 
common analytical technique used to separate and characterize proteins, using a discontinuous 
polyacrylamide gel as support medium and SDS to denature the proteins. SDS (also called lauryl 
sulfate) is an anionic detergent bound by a polypeptide chain in proportion to its relative molecular 
mass. The negative charges on SDS destroy most of the complex structure of proteins and are 
strongly attracted toward an anode in an electric field. Polyacrylamide gels restrain larger 
molecules from migrating as fast as smaller molecules. Because the charge-to-mass ratio is nearly 
the same among SDS-denatured polypeptides, the final separation of proteins is dependent almost 
entirely on the differences in relative molecular mass of polypeptides. In a uniform density gel, the 
relative migration distance of a protein (Rf) is negatively proportional to the log of its mass. The 
relationship between Rf and mass can be plotted running proteins with an unknown mass and a 
known mass simultaneously, so that the masses of unknown proteins can be estimated. Protein 
separation by SDS-PAGE can be used to estimate relative molecular mass, to determine the 
relative abundance of major proteins in a sample and to determine the distribution of proteins 
among fractions. Acrylamide is used for preparing electrophoretic gels to separate proteins by size. 
Acrylamide mixed with bisacrylamide forms a cross-linked polymer network when the polymerizing 
agent, ammonium persulfate, is added. The ammonium persulfate produces free radicals faster in 
the presence of TEMED (N,N,N,N'-tetramethylenediamine). The size of the pores in a gel is 
inversely related to the amount of acrylamide used. Very large polypeptides cannot penetrate far 
into a gel and thus their corresponding bands may be too compressed for resolution. Polypeptides 
below a particular size are not restricted at all by the gel, and regardless of mass they all move at 
the same pace along with the tracking dye. Gel concentration (%T) should be selected to resolve 
precisely proteins of interest. A typical gel of 7% acrylamide composition separates polypeptides 
with molecular mass between 45 and 200 kDa. There are two types of buffer systems used in 
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PAGE electrophoresis: continuous and discontinuous systems. A continuous system has only a 
single separating gel and uses the same buffer in the tanks and the gel. In a discontinuous system, 
a non-restrictive large pore gel, called stacking gel, is layered on top of a separating gel called 
resolving gel. Each gel is made with a different buffer, and the tank buffers are different from the 
gel buffers. The stacking gel has a lower concentration of acrylamide (larger pore size), lower pH 
and a different ionic content. This allows the proteins to be concentrated into a tight band before 
entering in the resolving gel. The resolving gel may consist of a constant acrylamide concentration 
or a gradient of acrylamide concentration (high percentage of acrylamide at the bottom of the gel 
and low percentage at the top). A gradient gel is prepared by mixing two different concentrations of 
acrylamide solution to form a gradient with decreasing concentrations of acrylamide. As the 
gradient forms, it is layered into a gel cassette. This latter gel is recommended for separation of a 
mixture of proteins with a greater molecular weight range. 
In our experimental conditions, continuous gel was running under reducing and denaturant 
conditions. Gel preparation procedures and running conditions used are described in the following 
protocol: 
 Assemble glass plate sandwich using two clean glass plates and two 75 mm spacers. Assemble 
the casting frame and stand as described by manufacturer. 
 In a clean falcon, prepare the resolving gel solution, mixing the ingredients as described in Table 4, 
remembering that AP and TEMED must be added at the end. Be careful not to generate bubbles. 
 Pour the resolving gel to a level about 1 cm from the top. Wait 1 min, then layer the top of the gel 
with saturated butyl alcohol (this will help the gel to solidify quickly in the absence of air). 
 Wait another 15-20’ for the gel to polymerize. Pour off the top layer of butyl alcohol and rinse with 
distilled water. Dry off as much of water as possible, using absorbent paper. 
 In a clean falcon, prepare the stacking gel as described in Table 4, being careful not to generate 
bubbles. 
 Pour the resolving gel till the space is full, then put in the appropriate comb. (The difference of pH 
in the two layers causes the stacking of the proteins. Thus, if the proteins are not stacking properly 
check the buffers pH). 
 Allow the top portion to solidify and then carefully remove the comb or store at 4°C in humidified 
condition, until use. 
 Place gel in opposite side of apparatus (Mini-PROTEAN 3-Cell, Bio-Rad). 
 Slowly add 1X Running buffer. 
 Load samples and molecular weight marker. 
 Run the gel at 60V until the blue dye overpass stacking phase, and then run it at 110 V until the 
blue dye reaches the bottom or runs off. At this time, the run is stopped, cables removed. The gel is 
removed from the cassette and can be processed for western blotting. 
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Table 4. Resolving and Stacking gel solution recipes. 
Reagents Running gel (1x) 
Stacking 
gel (1x) 
Acrylamyde 
percentage 
7% 10% 12% 15% 3% 
dH2O (ml) 7.2 15.3 12.3 10.2 3.075l 
30%/0.8% 
Acrylamide/Bis 
(ml) 
7.5 7.5 7.5 7.5 1.25 
4x Lower Tris 
Buffer (ml) 
0.15 0.15 0.15 0.15 0.025 
10% SDS (ml) 15.0 6.9 9.9 12.0 0.67 
APS (ml) 0.15 0.15 0.15l 0.15 0.025 
TEMED (ml) 0.02 0.02l 0.02 0.02 0.005 
 
  
 
 
Western blotting and protein detection   
The term “blotting” refers to the transfer of biological samples from a gel to a membrane and their 
subsequent detection on the surface of the membrane. Western blotting was introduced by Towbin 
and collegues [1989] and is now a routine technique for protein analysis. The specificity of the 
antibody-antigen interaction enables a single protein to be identified in the midst of a complex 
protein mixture. Western blotting is commonly used to identify a specific protein in a complex 
mixture and to obtain qualitative and semiquantitative data about that. The first step in a western 
blotting procedure is to separate the macromolecules using gel electrophoresis. Following 
electrophoresis, the separated molecules are transferred onto a second matrix, generally a 
nitrocellulose or polyvinylidene fluoride (PVDF) membrane. Next, the membrane is blocked to 
prevent any nonspecific binding of antibodies to the surface of the membrane. The transferred 
protein is complexed with an enzyme-labeled antibody as a probe. An appropriate substrate is then 
added to the enzyme and together they produce a detectable product such as a chromogenic or 
fluorogenic precipitate on the membrane for colorimetric or fluorimetric detection, respectively. The 
most sensitive detection methods use a chemiluminescent substrate that, when combined with the 
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enzyme, produces light. This output can be captured using film, a CCD camera or a 
phosphorimager designed for chemiluminescent detection. Whatever substrate is used, the 
intensity of the signal correlates with the abundance of the antigen on the blotting membrane. In 
our experimental procedure, western blotting and protein detection protocols are the following: 
 Cut a piece of nitrocellulose membrane (Hybond-ECL, Amersham Biosciences). Wet the 
membrane in dH2O. Soak membrane in 1X Transfer buffer for 10’. 
 Wet sponges, filter papers (slightly bigger than gel) in 1X Transfer buffer. Assemble sandwich 
(sponge-paper-gel-membrane-paper-sponge) for the electroblotting apparatus (Mini Trans-Blot 
Electrophoretic Transfer Cell, Bio-Rad). 
 Transfer for 1 h at 100 V with a cold buffer and frozen pack. 
 turn off power supply and remove cathode plate of blotter.  
 Staining the membrane with Ponceau’s dye and the gel with Coomassie Blue dye to verify the 
correct transfer. 
 Remove Ponceau’s staining washing the membrane with dH2O. 
 Block the nitrocellulose membrane in T-TBS (TBS with 0.05% Tween-20 V/V) containing 5% skim 
milk (w/v) for at least 1h on a rocking platform. 
 Wash 3 times the nitrocellulose membrane in T-TBS for 10’ each on a rocking platform. 
 Incubate the nitrocellulose membrane on a rocking platform with primary antibody diluted in T-TBS, 
overnight at 4°C. 
 Wash 3 times the nitrocellulose membrane in T-TBS for 10’ each on a rocking platform. 
 Incubate with secondary antibody horseradish peroxidase-conjugate diluted in 5% milk T-TBS for 
60-90’ on a rocking platform at room temperature. 
 Wash 3 times the nitrocellulose membrane in T-TBS for 10’ each on a rocking platform.  
 Wash the nitrocellulose membrane in TBS to remove the excess of tween. 
 Detect proteins incubating the membrane for 5’ with an enhanced chemiluminescence detection 
system (ECLTM, Amersham). 
 Place the blots in a sheet protector and exposed to Kodak X-Omat Blue Film (Blue X-ray Film) 
(Perkin Elmer) for different times. Several exposures allow better densitometric analysis. 
Autoradiography films are automated processed with an Automated x-ray film developer (Kodak 
M35A X-OMAT processor). 
 
 
Nitrocellulose membrane stripping 
Once visualized the proteins of interest, it is possible to strip off the first set of protein probes so 
that different proteins on the blot may be detected using a second set of specific probes. Stripping 
generally involves soaking the blot in a buffer that is sufficiently harsh to dissociate the affinity 
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interactions between antibodies and the target sample protein that was transferred to the 
membrane. The goal is to find a stripping condition that is efficient in removing the probes without 
also removing or damaging the target proteins on the blot. Because every antibody-antigen affinity 
interaction and target protein is unique, no one stripping condition is appropriate for all situations. 
Empirical testing and some optimization are necessary to determine appropriate stripping 
conditions for every particular western blot system. In most cases, conditions can be optimized to 
make at least one round of stripping and reprobing possible. In some cases, several rounds of 
stripping and reprobing are possible. 
In our experimental condition, the stripping protocol consists in: 
 Wash abundantly the nitrocellulose membrane with T-TBS on a rocking platform. 
 Incubate the membrane with Stripping Buffer at 50°C for 30’. Add 0.5 M NaCl to the stripping 
buffer slightly reduces the background from multiple probings. 
 Wash abundantly the nitrocellulose membrane with TBS on a rocking platform. 
 Return to membrane blocking and primary antibody incubation as previously described. 
 
 
Densitometric analysis 
Exposures of the same membrane for different times were acquired using GelDocTM image 
capture system (Bio-Rad), following Manufacturer’s instructions. The autoradiograms were 
quantified using Quantity OneTM and Image J software. The data were then analyzed with 
suitable statistic methods.  
 
Polyacrylamide gel staining 
After western blotting procedure, gel staining allows to verify the correct loading of protein 
samples and the correct protein transfer to nitrocellulose membrane. A commonly used stain for 
detecting proteins in polyacrylamide gels consists in 0.1% Coomassie Blue dye in 50% methanol 
and 10% glacial acetic acid. Acidified methanol precipitates the proteins. Staining is usually 
performed overnight on a rocking platform. The dye penetrates the entire gel, and sticks 
permanently to the proteins. Excess dye is washed out by destaining procedure with acetic 
acid/methanol washes on a rocking platform. Destaining in two steps (first using 50% methanol, 
10% acetic acid for 1-2 h and then using 7% methanol, 10% acetic methanol) provided a better 
efficiency. Finally, gels can be dried or photographed for later analysis.  
 
4.11 Statistical Analysis  Data are expressed as means ± SEM. The two way analysis of variance 
(Anova) and Bonferroni’s post-test were applied using Prism 5 software (GraphPad Software Inc, 
La Jolla, USA) assuming a p value less than 0.05 as the limit of significance. 
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5. Results 
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5.1 Derivation of GFP positive Post-Mortem Neural Precursor Cells and 
Characterization of their Self-Renewal capability 
Adult C57BL/6-Tg(UBC-GFP)30Scha/J mice were anesthetized and then killed 
by cervical dislocation. The cadavers were maintained at room temperature 
(25°C)  for 6 hours, and after this period of time their brains were  extracted, the 
area encompassing the SVZ surrounding the lateral wall of the forebrain ventricle 
was dissected and neural precursors were obtained as described in material and 
methods and according to Gritti et al 1996 and 1999.  
Post-mortem Neural precursors cells expressing green fluorescent protein (GFP 
PM-NPCs) proliferate in response to FGF-2 and EGF exposure, and formed 
typical spheroids similar to those formed  by NPCs obtained from CD1 mice and 
defined as neurospheres (Figures 21 and 22; Marfia et al 2011). 
 
Figure 21. Live images isolated precursors from SVZ of Adult C57BL/6-Tg(UBC-
GFP)30Scha/J mice. Pictures were taken 48 hours after cells isolation. Scale bars 200 µm.  
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Figure 22. GFP positive PM-NPCs are able to form neurospheres. Undifferentiated post mortem 
neural precursors cells isolated from the Sub Ventricular Zone (SVZ) of adult mice that 
constitutively expresses the green fluorescent protein (GFP) proliferate in response to growth 
factors (EGF and FGF-2) and form neurospheres. Scale bars 100 µm. 
To assess for self-renewal, individual primary spheroids were mechanically 
dissociated, and  cells were plated in growth medium at the density of 3000 
cells/cm2 in 500 ml and, the cultured for for 4-5 days at 37 °C in a humidified 5% 
CO2 atmosphere. The spheroids formed after 4-5 days were harvested and 
counted (Figure 3). The number of neurosphers formed by GFP-positive PM-
NPCs was 169 ± 7,63/well and was similar to the number of spheres formed by 
both classical neural stem cells (NPCs) and post mortem neural precursors cells 
from CD1 mice (Figure 23 and Marfia et al 2011).  At each passage 
neurospheres were harvested by centrifugation and mechanically dissociated by 
pipetting and cells were plated again. This assay was performed at passage 7, 
17 and 30 without observing any significant difference.  
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FIGURE 23. Neurosphere forming assay. PM-NPCs population analysis was performed by 
counting the total number of neurospheres generated in 10 culture days. Classical neural stem cells 
from SVZ of adult CD1 mouse (NPCs; Gritti et al 1996), post mortem neural precursors cells from 
SVZ of adult CD1 mouse (PM-NPCs, Marfia et al 2011) and post mortem neural precursors cells 
from Adult C57BL/6-Tg(UBC-GFP)30Scha/J  mouse (GFP+ PM-NPCs) were cultured in the 
presence of EGF, and FGF-2; the number of spheres formed in each well was counted after 7–12 
days.  It is represented by the number of neurospheres generated by 3000 cells plated in a single 
well. The experiment was performed three times in triplicate for each cell source and was repeated 
at passage 7, 15 and 30 without observing significant differences in growth and markers expression 
(data not shown). Data are expressed as the mean of three independent experiments with similar 
results reporting ± standard error. 
 
5.2 GFP positive PM-NPCs differentiation features 
In order to assay for multipotency GFP PM-NPCs were induced to differentiate as 
briefly reported below . Neurospheres were mechanically dissociated and cells 
(1x 104 cells/cm2) were seeded onto Matrigel®-coated glass coverslips (12 mm 
diameter) in the presence of FGF-2. After 48 hours of growth culture in presence 
of growth factors cells were shifted into the differentiation medium in which FGF-2 
and EGF were substituted with serum (1%; FBS) (Invitrogen). After growth 
factors removal and serum supplement, PM-NPCs attach to the dish and begin 
the differentiation process into neurons, astrocytes, and oligodendrocytes in a 
typical cell linage ratio (as reported in Marfia et al 2011). The differentiation 
capability of PM-NPCs was evaluated by monitoring the percentage of cells 
expressing MAP-2, GFAP, and NG2 markers, after 7 and 15 days growth in 
differentiation medium without growth factors (Figure 24). The quantification of 
neuronal-like differentiation after 7 days is shown in panel B of Figure 4. MAP-2 
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positive neurons were 39,3 ± 0,77 %; GFAP (astrocytes) and NG2 
(oligodendrocyte precursors) -positive cells were 60,9 ± 2,81and 12,86 ± 0,48 
respectively. The extent of the GFP PM-NPCs differentiation confirmed that these 
precursors cells have similar features of that previously obtained and described 
(Marfia et al 2011). 
 
Figure 24. Neural marker expression after differentiation induction. After removal of growth 
factors, PM-NPCs neurospheres readly differentiates into MAP2 positive neurons, NG2 labelled 
oligodendrocytes precursors and astrocytes (GFAP). Staining with specific markers is showed in 
by counting the number of cells positive for each marker staining after 15 days of differentiation. 
Marker positivity was expressed as a percent of the total cells.  The quantification  indicates that 
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about 40 % of  PM-NPCs differentiates into neurons. Data are expressed as the mean of three 
independent experiments with similar results ± standard error.  
 
5.3 PM-NPCs Striatal Transplants Ameliorate the Behavioral Symptoms of 
MPTP-Lesioned Mice 
The flow chart reported below describes the experimental plan followed to 
investigate the effects of GFP positive PM-NPCs transplanted in an experimental 
model of Parkinson’s disease. 
 
 
 
As control, before transplantation the expression of tyrosine hydroxylase (TH), 
the key enzyme in the synthesis of dopamine and markers of dopaminergic 
neurons, was investigated by immunocytochemistry assay in GFP PM-NPCs 
neurospheres. As showed in figure 25 these neurospeheres were not stained by 
specific antibody against TH; instead, as expected, were positive to the 
expression of nestin, the typical stem cells marker. 
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Figure 25. PM-NPCs do not express tyrosine hydroxylase.  PM-NPCs cositutively expressgreen 
fluorescent protein and for that reason are showed in green. The labelling for nestin and tyrosine 
hydroxylase are showed in red. Nuclei were stained with DAPI and are showed in blue. The 
experiment was performed in duplicate with similar results and the picture showed here are 
representative. Scale bars are 100 microns. 
For transplantation GFP PM-NPCs neurospheres were mechanically dissociated, 
cells were counted by trypan blue exclusion and then were suspended in PBS at 
the concentration of 1x105 cells/5l. Cells were injected into the striatum of MPTP 
mice. To test the effect of transplanted PM-NPCs on the behavior of MPTP-
lesioned mice, we performed a series of behavioral tests on each mouse before 
and after transplantation or treatment.  
Figure 26 shows the Image of the horizontal grid test apparatus, inverted.  
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Figure 26. Scheme of horizontal grid used in the behavior evaluation (modified from Tillerson 
JL 2002 and Tillerson et al 2003) 
Once the mouse firmly grabbed on the grids with all four paws, the apparatus 
was inverted upsidedown and the animal is videotaped for a maximum duration 
of 30 seconds (Figure 27).  
 
Figure 27. Position of the animal for the horizontal grid test at the starting of videotaping. 
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With each weight-bearing step, the paw may fall or slip between the wire. This 
was recorded as a foot fault. The total number of steps (movement of each 
forelimb) that the mouse used to cross the grid was counted, and the total 
number of foot faults for each forelimb were recorded. This test was performed 
every 2 days before and after the transplants. Healthy animals tend to move 
along the grid with great ease exploring the whole territory for which the 
residence time in the vicinity of the side walls, that damage their security is 
reduced compared to that of animals that following the lesion with MPTP have 
coordination problems motor. This reduced safety of lateral displacement 
reduces their ability exploratory and increase the time of stay at the safe haven 
represented by the side wall. This behavioral problem is the direct consequence 
of the reduction of dopamine levels in the striatum following the lesion with the 
neurotoxin MPTP. As showed in the histogram reported in  figure 8 the behavior 
impairment  due to the first injection of MPTP start to be significant 3 days after 
the administration of the drug, that correspond to a 20% percent of  forepaws 
fault in MPTP injected animals (p<0.05 vs control mice, CTRL). Then the percent 
of forepaws fault reach the 30% at day 9 (p<0.01 vs CTRL). The effect of 
transplant of PM-NPCs is rapid and determines a significant improvement of 
animal behavior by decreasing the percent of forepaws fault from 45% in PBS 
treated animals to about the 25% in PM-NPCs treated animals (p< 0.05 PM-
NPCS injected group vs PBS injected group). The improvement in transplanted 
animals group is maintained for all the period of observation reaching values 
similar to the control animals (healthy mice) after two weeks (14,5 % of forepaw 
fault at days 21 and 23) (Figure 28). 
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Figure 28. PM-NPCs reduce the percent of forepaw fault  in transplanted animals. 
The table under the graphs show the number of animals evaluated in each group. Data are 
expressed as the mean of two independent quantification (two independent observers in 
blind ) with similar results ± standard error (* p<0.05 MPTP and vs CTRL  from day 0 to 
day 9; * p<0.05, ** p<0.01 MPTP vs PM-NPCs treated animals).  
 
The Vertical Grid Test, whose technique has been widely described in materials 
and methods, has enriched our results confirming the data described above. The 
schematic of the vertical grid apparatus is showed the figure 29. 
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Figure 29. Scheme of vertical grid used in the behavior test (from Kim et al 210). 
In vertical grid test mouse is placed 3 cm from the top of the apparatus, facing 
upward, and is videotaped while it turned around and climbed down (Figure 30). 
The score that was reported was the time required to climb down. MPTP-treated 
mice took longer to make a turn on the vertical grid. 
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Figure 30. Position of the animal for the vertical grid test at the starting of videotaping. The 
mouse is placed 3 cm from the top of the apparatus, facing upward (A); then it has to turn around 
and climb down (B). 
As showed in the histogram reported in figure 11 significantly longer time to turn 
head down and to climb down was observed in the MPTP-treated mice compared 
to the control animals. In normal conditions, healthy animals (CTRL) took 
approximately 27 seconds (as a mean of the analyzed animals) to turn and to 
climb down from the top of the grid (Figure 31). Figure 11 shows how the lesion 
strongly modify the animals ability to control their actions when hung on the grid 
and their ability to turn around and climb down. The impairment due to the MPTP 
injection become significantly evaluable in the same day of injection and the 
animals of this group (n=20) employed a mean of 75 seconds to perform the test 
(p<0.01 MPTP vs CTRL). The impairment increases during time and it is 
stabilized by the second injection of MPTP (20mg/kg i.p.) performed at day 7 
(see experimental plan showed at the beginning of the Results paragraph).  
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Figure 31. PM-NPCs reduce the time required to climb down from the vertical grid  in 
transplanted animals. The table under the graph shows the number of animals evaluated in each 
group. Data are expressed as the mean of two independent quantification (two independent 
observers worked in blind) with similar results ± standard error (** p<0.01, *** p<0.001 MPTP  vs 
CTRL  from day 0 to day 9; ** p<0.01 and p<0.001 MPTP vs PM-NPCs treated animals). 
 
The application of the cells counteracts the effect of  the drug. As showed in 
horizontal grid test also in the vertical grid test animals treated with PM-NPCs 
showed an significant improvement starting at day 3 after injection, with a 
reduction of the time to perform the test at 50 seconds (Figure 31). As showed for 
horizontal grid test the behavioral recovery is stable for the following 10 with an 
improvement at days 21 and 23 reaching levels performed by healthy animals 
(Figure 31). 
 
The recovery of behavioral deficits was also investigated by means of the 
forepaw stride length test. The mice feet were dipped in red ink and they were 
placed in a 1 meter long runway that was covered with paper to capture the mice’ 
footsteps. The length of stride between experimental and control groups was 
measured and was plotted in the histogram showed below. At two weeks after 
transplantation we found that the stride length of the PM-NPCs treated mice 
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increased after cell transplantation (n = 4) and was significantly longer than that 
of the MPTP group mice (n = 4) (Figure 32). 
 
Figure 32. Stride length of Forepaw. Representative runs of MPTP lesioned mice untreated and 
treated with PM-NPCs at day 21. At days 21 and 23 The length of stride was significantly higher in 
mice  injected with PM-NPCs cells (n = 4) than in MPTP mice (n=4). Data are expressed as the 
mean ± standard error (*p<0.05  MPTP vs PM-NPCs treated animals).  
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5.4 PM-NPCs transplantation does not  affect MPTP-mediated dopamine 
loss  
At the end of the observational period (2 weeks after PM-NPCs engraftment, day 
24) some of the animals were killed by cervical dislocation, brains were removed 
and striatal areas (left and right striatum) were dissected-out separately and 
immediately frozen in liquid nitrogen. After homogenization the individual 
intrastriatal content of dopamine (DA) and related metabolites (DOPAC, 3MT and 
HVA) was determined by High Performance Liquid Chromatography (HPLC) 
following the procedure described in Materials and Methods. The effect of MPTP 
administration on DA relative metabolites content after 2 weeks from the 
neurotoxin administration is shown in figure 33. In agreement with previous 
reports by other authors (Corsini et al. 1985, 1987 and Viaggi et al. 2009)  levels 
of DA ranged around to 100ng/mg of proteins in normal striatum. MPTP 
treatment causes a decrease of DA to 51,2 ng/mg proteins (about 50% decrease 
in striatal DA content compared with control levels) (Figure 33A). These results 
consolidate the observations obtained in behavioral tests (Figures 28, 31 and 
32). PM-NPCs transplantations improve recovery of function without promoting 
the recovery of DA content, both into the left and right striatum (Figure 33A). Also 
the content of DA metabolites into the striatum of cells-grafted animals remains 
similar to that of MPTP-saline treated animals.   
In the same tissue extracts 5-hydrossitriptamine, noradrenaline and their 
metabolites were also determined. Panel B of figure 33  shows that MPTP and 
PM-NPCs-treated groups do not differ significantly.    
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Figure 33. Effect of PM-NPCs transplantation on striatal tissue levels of DA and its 
metabolites.  The levels of DA in the striatal areas (left and right, individually evaluated) 
were assessed by HPLC. The graph shows a significant decrease in DA content in MPTP 
group compared to the aged-matched controls. The cells graft does not determines a 
recovery of DA content. The number of animals utilized for the determination are reported in 
the table below the graphs. DA content was measured relative to the amount of proteins in 
the samples (ng/mg proteins). Data are expressed as mean ± SEM . *p< 0.05, ** p<0.01, 
***p<0.001 versus control group (CTRL). 
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Figure 34. Effect of PM-NPCs transplantation on midbrain levels of catecholamines 
and their metabolites.  The levels of neurotransmitters in midbrain were assessed by 
HPLC. Catecholamines content was measured relative to the amount of proteins in the 
samples (ng/mg proteins). Data are expressed as mean ± SEM . ns= not significant. **p<0.01 
vs CTRL. 
 
 
5.5 Intrastriatal localization of transplanted PM-NPCs 
Approximately 100,000 cells were injected into the striatum of each animal and I 
found that many of the transplanted cells did survive 2 weeks after the 
transplantation. The vast majority of the GFP+ cells were found in the striatum.  
The morphology of the surviving PM- NPCs cells and at 2 weeks post-
transplantation, the cells appeared more mature with an oval soma and abundant 
neuritic processes extending 30 µm from the cellular soma (Figure 35). Healthy 
animal brains and lesioned animal brains injected or not with PM-NPCs were 
sectioned by means of cryostat. Coronal sections containing the striatum, were 
immunodecorated with anti- tyrosine hydroxilase (TH) antibody. As expected the 
immunoreactivity to the TH significantly decreased into the striatum of MPTP 
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animals, while it resulted lightly increased into the striatum of cells transplanted 
animals (Figure 36). 
 
Figure 35. Intrastriatal localization of transplanted PM-NPCs.  
 
 
Figure 36. Tyrosine hydroxylase expression analyses into the striatum after PM-NPCs 
transplantation.  
Moreover, considering the details showed in the figure 37 it is possible to 
appreciate that many PM-NPCs resulted positively decorated by the anti-TH 
antibody. Thus, this suggests that 2 weeks after transplantation a part of grafted 
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PM-NPCs were differentiated. This is also confirmed by the morphology of the 
cells (see yellow arrows in the enlargement of figure 37) 
 
Figure 37. PM-NPCs expresses TH two weeks post-transplantation. 
 
5.6 Most Transplanted PM-NPCs Develop into neurons 
The fate of transplanted cells was investigated by means of immunoistochemical 
analyses into the striatum coronal sections by investigating the expression of cell 
specific differentiation markers. As showed in figure 18 most of transplanted PM-
NPCs resulted positively decorated by the anti-MAP2 antibody (a marker of 
neuronal differentiation) and some cells were positive to the NG2 (the marker of 
oligodendrocytes precursors). The quantification showed that the grafted cells 
differentiate mostly in neurons: 71,88 % ± 2,3 % of GFP positive cells resulted 
positive for MAP-2 expression, instead 38,77% ± 3,8 % of GFP positive cells 
were positive for NG2 expression (Figure 38). 
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Figure 38. Most PM-NPCs adopted a neuronal Fate when Transplanted into the Adult 
Striatum.  Two weeks after transplantation, most PM-NPCs expressed the neuronal markers MAP-
2 (71,88% ± 2,3%). Scale bar represents 100 m.   
Two weeks post-transplantation some grafted cells into the striatum resulted also 
positive to the labelling with anti-NeuN, the mature neuronal marker (Figure 39). 
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Figure 39. Transplanted PM-NPCs express NeuN. Two weeks after transplantations some 
intrastriatal grafted cells were decorated by anti-NeuN antibody. Scale bar represents 100 m  
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We also found that most of the transplanted cells expressed the marker related to 
dopamine synthesis such as tyrosine hydroxylase (TH) (47,88% ± 11%, n= 311 
cells), the majority of transplanted cells resulted to express the cholinergic 
interneuron marker ChAT, which is expressed by striatal excitatory interneurons 
(58,33%± 8%, n= 289 cells), and a relative lower amount of cells expressed 
GABA a marker of GABAergic neurons (35% ± 4%, n= 254 cells) (Figure 40).  
 
Figure 40.  Most PM-NPCs express cell specific markers after transplantation into the Adult 
Striatum. 
 
5.7 Transplanted PM-NPCs Migrate throughout the Striatum and in 
Substantia Nigra pars compacta 
By means of confocal analyses on coronal, longitudinal and transversal sections 
of transplanted animal brains we investigated the migration features  transplanted 
neural precursor cells. At 2 weeks after transplantation we observed that grafted 
PM-NPCs were able to move away from the injection site through the impaired 
striatum (Figures 41 and 42).  Differently from what it was observed for other 
authors with other grafted cells, such as the one isolated from the embryonic 
medial ganglionic eminence (MGE cells; Martinez- Cerdeno et al 2010), 2 weeks 
post-transplantation many GFP-PM-NPCs had migrated to 2.0 to 2.5 mm 
following the ventral direction (Figure 41).  
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After re-assembly  longitudinal sections obtained by confocal acquisition we were 
able to observe that 2 after transplantation PM-NPCs moved away from the site 
of injection following rostro-caudal and rostro-ventral pathways, that seems to be 
specific (Figure 42) for distance longer than 1 mm.  
 
 Figure 41. Coronal sections assembly showing the intrastriatal migration of PM-NPCs 
 grafted cells. 
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  Figure 42. Sagittal sections assembly showing the intrastriatal migration of PM-NPCs 
grafted cells. 
Further by means of confocal analyses performed on transversal brain sections 
of PM-NPCs grafted animals we assessed that two week after transplantation 
cells were able to migrate beyond the borders of the striatum and some of them 
were found into the Substantia Nigra pars compacta ipsilateral and contralateral 
to injection site (Figure 43). 
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Fig 43. Transplanted PM-NPCs migrate beyond the borders of the striatum. (A) Picture 
showing the mouse brain transversal sections with the site of localizations of PM-NPCs two weeks 
after transplantation. (B) Enlargement of pictures showed in the upper panel. PM-NCs are green 
and in red is showed the immunoreactivity to NeuN antibody. Nuclei are stained with DAPi (blue). 
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5.8 Transplanted PM-NPCs Migrate in the Ventricular Zone 
 In rodents and in non-human primate the lateral ventricle is the larger area of 
adult neurogenesis; that is called, the subventricular zone (SVZ). This region 
lines the lateral ventricles of the forebrain and is comprised of three main cell 
types. The multipotent, type B astrocytes, that have been identified as the bona 
fide SVZ stem cells, give rise to fast-cycling transiently proliferating precursor 
cells that are called type C precursors and that, in turn, generate mitotically active 
type A neuroblasts. The type A cells, while dividing, migrate tangentially towards 
the olfactory bulbs where they integrate as new interneurons. In addition adult 
neurogenetic region is found in the subgranular zone (SGZ), which is located 
within the dentate gyrus of the hippocampus. A number of studies have shown 
that dopamine receptors (D2 and D3) are expressed on neurospheres derived 
from reodents SVZ precursors, suggesting that dopamine can act directly on 
these cells (Kippin et al 2005 and Coronas et al 2004). Moreover, in vivo studies 
have shown the expression of D2-like, D1-like and D3 receptors  in the SVZ of 
both rats and mice (Diaz et al 1997, Hoglinger et al 2004, Kim et al 2010). It has 
been shown that in adult mice the administration of MPTP reduces the number of 
proliferating cells in the SVZ (Hoglinger et al., 2004).  With the aim to investigate 
the role of transplanted PM-NPCS we found that these cells are able to reach the 
SVZ of MPTP lesioned mice and are positive to the staining of Nestin antibody 
suggesting that in this area these are maintain the state of precursors cells 
(Figure 44).  
 
 
Figure 44: Localization of intrastriatal injected PM-NPCs in Lateral Ventricle of SVZ. 
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5.9 PM-NPCs and inflammation 
After PM-NPCs transplantation in animal model of spinal cord injury in which we 
observed that grafted stem cells were able to influence the expression both 
inflammatory and anti-inflammatory some cytokines (Carelli et 2013 submitted). 
Moreover, a considerable literature suggesting that a local immune reaction 
occurs in affected regions of the brain in Parkinson's disease (PD) is available 
(for review see Hirsh et al. 2012 and Collins et al. 2012). Therefore we aimed to 
attempt whether one of the actions of transplanted PM-NPCs in our experimental 
model of Parkinson disease would be the regulation of neuroinflammatory 
process.  Accordingly, we performed a new set of PM-NPCs injections was 
performed and animals were killed by cervical dislocation 24, 48 hours and 7 
days after grafting. Brains were rapidly removed and some area such as left and 
right striatum, frontal cortex and mesencephalon were dissected and immediately 
frozen in liquid nitrogen (see materials and method paragraph for detailed 
protocol). The mRNA levels of cytokines was quantitatively assayed by means of 
real time RT-PCR. The comparison was made between the treated with PBS or 
PM-NPCs. As additional controls, we assayed the cytokines in the same brain 
regions of healthy animals. This part of the work is still in progress and figure 45 
shows some results obtained until now relative to the striatal areas investigated 
individually.  As expected  the assayed cytokines, namely IL-6, IL-10 and IL-15 
were increased in the striatum of  lesioned animals 7 days after the PM-NPCs 
transplantation.   
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Figure 45. Transplanted PM-NPCs do not modify the expression of inflammatory cytokines. (A) 
mRNA levels of indicated cytokines were investigated 7 days after cells transplantations. Data are 
expressed as the mean of at least three  independent quantifications with similar results ± standard error 
(** p<0.01, *** p<0.001are vs CTRL; ns= not significant). (B) number of animals evaluated in each group. 
(C) Behavioral test performed as control.  
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6. Discussion 
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 The aim of this study was the evaluation of the repair ability of post mortem neural 
precursors (PM-NPCs) in a model of Parkinson’s disease created by the administration 
of the neurotoxin MPTP. 
We described that following their administration PM-NPCs survived and differentiated 
in neural like cells in the injection area (about 72 % were MAP-2 positive). Part of them 
even migrated to very distal area such as the ispilateral and contralateral Substantia 
Nigra (SN). Differentiation was specific for the area of injection, most of the cells 
become tyrosine hydroxylase (TH) positive (47,88±11 %),  and some of them become 
cholinergic (58,33±8% were ChAT positive) and gabaergic (35±4 were GABA positive). 
There was also the co-expression of more than one neurotransmitter related enzyme. 
In detail, 20% of TH positive cells were also ChAt positive.  
From the behavioral stand point the effect of PM-NPCs was rather quick. After 10 days 
of MPTP administration mice were unable to properly place their forepaw and hind 
limbs on the horizontal grid test and unable to properly descend when positioned on 
top of the vertical grid. Such a behavioral deficit was maximal at 10 days after lesion 
and maintained unmodified thereafter in the group of cell untreated mice. Differently, 
the behavioral recovery occurred within 72- 96 hours after PM-NPCs administration. 
Within 7 days  behavioral parameters were totally comparable with the control not 
lesioned animals. Also the walking parameters evaluated by measuring the stride 
length was normalized within 4 days following cells administration. The behavioral 
effects are likely unrelated to the changes of neurotransmitters loss caused by MPTP 
intoxication. The  HPLC analyses have unequivocally shown that MPTP administration 
caused about 50% loss of dopamine content in the striatum, and such a decrease is 
not modified in the lesioned animals that were subsequently treated with PM-NPCs. 
Similar results were obtained for 5-HT and noradrenaline. Thus this suggests that the 
repair action of PM-NPCs may not be mediated by the restoration of dopamine levels in 
the striatum but rather in a novel mechanism that may be represented by an enhanced 
efficacy in the synaptic transmission of the surviving dopaminergic axon terminals, 
perhaps through an improved signal transduction mechanism. This is also supported 
by our finding that lesion causes only a mild change in inflammatory parameters and 
neurotrophic factors and that such parameters are only modestly affected by cellular 
transplantation.  
Regenerative medicine is an emerging interdisciplinary field of life sciences with the 
aim of healing impaired function in the body (Haseltine 2003; Gutmann et al. 2005). 
The regeneration of tissues and organs offers a radical new approach for the treatment 
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of many resulting from any cause, including congenital defects, disease, and trauma. It 
uses a combination of several technological approaches that moves it beyond 
traditional transplantation and replacement therapies that may include the use of stem 
cells.  
Originally described in 1817 by James Parkinson (Parkinson, 1817), Parkinson’s 
Disease (PD) is a neurodegenerative disease that afflicts more than one million people 
in the United States, with over 60,000 new cases being diagnosed each year (XXX). In 
Italy the prevalence of PD was 230.000 cases in 2012 and it has been estimated that 
the number of cases will double in 2030 (Abruzzese et al. 2013). PD causes the nerve 
cells that generate dopamine to degenerate and die, leaving patients with limited 
muscle control. PD generally affects the elderly with the average onset occurring 
around age 60, although early onset cases do occur. Patients suffer from numerous 
side effects that have a strong and continued impact on their quality of life. These 
include uncontrollable muscle tremors and twitching, loss of facial expression, poor 
balance, trouble swallowing, pain and loss of movement control. While PD is not lethal 
and patients can live with the disease for over 20 years, the burden on patients and 
their families is significant. There is currently no cure for Parkinson’s and treatments 
are limited to managing symptoms rather than addressing the underlying cause of the 
disease. Patients have to cope with frequent medication changes and side effects to 
manage (and not eliminate) the primary symptoms of this disease, resulting in a 
condition that is extraordinarily difficult to control on a chronic basis. PD can be caused 
by inherited genetic mutations (recently revised in Badger et al 2014), or be idiopathic 
with no known cause. There is also likely a strong contribution of environmental factors 
in PD. For example, the pesticide rotenone can be used to induce Parkinsonism in 
animal models, and some links have been shown between rural living or agricultural 
work and PD (Pezzoli and Cereda, 2013).  
Stem cells are defined as undifferentiated cells endowed with continuous self-renewal 
ability and pluri- or multipotentiality  (Hall and Watt, 1989). Moreover, in response to 
proper stimuli stem cells are able to produce more specific progenitor cells that can 
further differentiate into one or more functional cell types and could consequently give 
rise to a wide panel of cell types, including neural cells. Research on adult stem cells 
has generated a great deal of excitement. Scientists have found adult stem cells in 
many more tissues than they once thought possible. This finding has led researchers 
and clinicians to ask whether adult stem cells could be used for transplants. 
Regenerative medicine currently take advantage of the stem cells usage following 
three different approaches (Stocum, 2004): the implantation of stem cells to build new 
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structures, the implantation of cells pre-primed to develop in a given direction, and the 
stimulation of endogenous cells to replace missing structures. However, stem cell 
research has been controversial and has raised ethical dilemmas primarily concerning 
the creation, treatment, and destruction of human embryos inherent to research 
involving ES cells. There has been a long history of fetal tissue transplantation for the 
treatment of patients with advanced PD. Despite the wake of a long series of 
encouraging open-label studies, initial enthusiasm for cell replacement therapy by 
grafting fetal neuronal precursor cells into the striatum has vanished after two double-
blind placebo controlled clinical trials showing only moderate symptomatic 
improvement and the occurrence of severe disabling dyskinesia (revised in Barker et 
al., 2013). Moreover, adult stem cells have great potential because of their self-renewal 
and self-replication abilities as well as their pluripotency. Furthermore, the use of adult 
stem cells is not limited only by ethical considerations. Several protocols have been 
described to generate TH-positive neurons from ESCs (Cai et al. 2009, Friling et al., 
2009), and several studies have demonstrated the differentiation of NSCs and MSCs 
into neurons, astrocytes and oligodendrocytes (Barzilay et al., 2009; Jiang et al, 2010); 
the transplantation of these induced cells into animal models of PD has resulted in 
some therapeutic effects improving the animals impairment. In view of such results few 
years ago we aimed at the isolation of adult neural stem cells capable of surviving in a 
highly unfavorable environment. We have isolated adult neural stem cells from SVZ 
several hours after death of the mouse donor (Marfia et al. 2011). This procedure 
provides a population of NSCs, called post mortem neural precursors (PM-NPCs), that 
differentiate in vitro preferentially in neurons  and such process is dependent on the 
autocrine EPO release (Marfia et al 2011). 
Data reported in this study were obtained by performing analyses two weeks after cells 
transplantation and can be considered a part of a more detailed investigation in which 
the effects of such  transplants will be investigated after longer time period from the 
cells implantation such as 30 and 70 days. These evidence will allow to make a 
comparison with other stem cells type that have been previously transplanted by other 
groups, such as classical embryonic neural stem cells, embryonic medial ganglionic 
eminence (MGE) cells  (Campbell et al., 1995; Olsson et al., 1997; Wichterle et al. 
1999; Alvarez-Dolado et al. 2006; and Martınez-Cerdeno et al 2010).  
Considering MGE cells, the effect of their transplantation in the striatum of 6-
hydroxydopamine (6-OHDA) rat has been explored by many research groups in the 
past. For example, Campbell et al. (1995) injected MGE cells into the lateral ventricle of 
mouse embryos and found that grafted cells survived, and were not able to migrate 
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throughout the striatum. Olsson et al. (1997) transplanted mice MGE cells into the 
striatum of postnatal day 1, 7, and 21 rats and reported that the cells distributed widely 
he striatum. Wichterle et al. (1999) transplanted mouse neuronal precursor cells from 
the MGE, lateral ganglionic eminence (LGE), and cortical ventricular zone into the adult 
striatum and found that only MGE cells possessed a unique capacity to migrate and 
differentiate into neurons. Alvarez-Dolado et al. (2006) showed that MGE cells 
transplanted into postnatal day 3 and 4 rats striatum differentiated into GABA positive 
neurons. More recently, Martınez-Cerdeno et al. (2010) showed that MGE cells 
transplanted in the striatum of adult 6-OHDA rats were able to survive for more than 1 
year  after the injection; these cells were mainly localized into the striatum and 
differentiate in inhibitory interneurons that functionally integrate into the striatum. In our 
experimental conditions we found that PM-NPCs transplanted cells two weeks after 
from the injection were found distributed in specific directions into the striatum (2,5 mm 
ventrally to the injection site). Moreover, we also found that these PM-NPCs overtake 
the striatum  margins reaching the SNpc were they show  a mature neuronal 
phenotype (NeuN expression). These evidences suggest that these cells are 
characterized by interesting migratory capabilities that allow them to reach damaged 
brain area.  Concerning preclinical cell therapy experiments on PD animals models, 
neural differentiation-based therapy protocols were performed using stem cells from 
Wharton’s Jelly (Fu et al., 2006), dental pulp (Wang et al., 2010) and bone marrow 
(Offen et al., 2007) that underwent various culture conditions before being transplanted 
in 6-OHDA-parkinsonian rats. Although behavioral and pathological enhancements 
were observed in most of the above cited studies on stem cells transplantation, the 
underlying mechanisms responsible were not sufficiently detailed, and there is not clear 
evidence for an appropriate integration into the lesioned central nervous system (CNS). 
Conversely, significant improvements were observed in PD animal models that were 
transplanted with bone marrow stem cells (BMSC) without any pre-differentiation step. 
In those conditions, no sign of neural differentiation was properly observed. Still, 
beneficial effects and rescue of dopaminergic neurons were noticed and mainly 
associated with neuroprotection (Park et al. 2011 and 2012), trophic support (i.e. glial 
cell line-derived neurotrophic factor (GDNF) or epidermal growth factor (EGF) secretion 
(Park et al., 2012; Baldini et  al., 2010) or anti-inflammation (attenuation of blood-brain 
barrier damages, microglia inactivation) (Chao et al. 2009). Moreover, BMSC graft 
induced proliferation and migration of endogenous SVZ neuroblasts in two PD animal 
models (Park et al 2012; Cova et al. 2010).  
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PM-NPCs were obtained after donor death and show high differentiation capability 
compared to classical NPCs. These cells differentiate in vitro mostly in neurons and 
fewer cells show GFAP positive differentiation. This appears to be a specific process 
for several reasons: one is the number of floating spheres as parameter of neural 
features. We observed that there was not differences in neurospheres formation 
between PM-NPCs and NPCs (Figure 23). The second reason stems from the peculiar 
properties of PM-NPCs that is  the ability to produce and release erythropoietin (EPO). 
We had shown that PM-NPCs (differently form NPCs) synthetize EPO that once 
released is the factor that allow their neuronal differentiation. Since the blockade of its 
receptor or the elimination of EPO release by specific antibody blocks the 
differentiation completely. Indeed it is well known that EPO promotes proliferation of 
NPCs in vitro and in vivo (Bernaudin et al 1999; Sasaki et al. 2000;  Brines et al. 2000; 
Shingo et al. 2001; Gorio et al 2002, 2005) and that is related to the fact that all stem 
cells express the receptor for erythropoietin. Thus it is not surprising that the 
transplantation of PM-NPCs may have a favorable impact on behavioral recovery after 
their transplantation into the striatum dopamine depleted by means of MPTP. We must 
consider the enormous literature showing that in vivo administration of EPO promotes 
recovery of function after CNS lesionig (revision in Leist et al. 2004; Grasso et al. 2004; 
Brines and Cerami 2005; Carelli et al 2011) and mobilization of neural stem cells from 
the site of origin into the affected area. Thus, we suggest that the local release of EPO 
by PM-NPCs may have a dual effect, one is related to the local neurotrophic action on 
neurons and neural processes affected by MPTP and the other may be the migratory 
response of endogenous stem cells to the  area of PM-NPCs accumulation. This may 
be supported by the highly effective and rapid reparatory effect of transplantation 
occurring within four days. This is highly coherent with a local release of EPO while the 
migratory action of endogenous stem cells may be a secondary effect that may 
promote the reparatory action of transplants. 
The migratory pathway of PM-NPCs into the mouse brains is also suggestive of a 
protective action by the transplanted cells that may modify the  environment allowing 
such a distal migration. We must remind that cells within two weeks migrate more than 
2 mm, this is a very long distance in a very short period. Thus this suggest that the 
injection of PM-NPCs promotes the recovery of function in a model of Parkinson’s 
disease via a modification of the microenvironment in the striatum and in the connected 
brain structures. Such a modifications allow both an improved DA signal transduction 
that is the only explanation for behavioral recovery and molecules changes that allows 
stem cells to migrate through the brain. One of the major points for  the future 
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investigations will be the  evaluation of the locally released EPO by PM-NPCs. The 
silencing of EPO in PM-NPCs will be performed in the next future. 
This study provides new evidences that will be useful for developing cellular PD 
therapies. Future studies should further explore the clinical potential role of the 
investigated post mortem neural precursors cells  in order to provide new perspectives 
on PD treatment. 
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